摩熵医药(原药融云)-生物医药全产业链数据服务平台

<!DOCTYPE html> <html lang="zh-CN"> <head> <meta charset="utf-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=1.0,user-scalable=0" id="vp"> <meta name="google" content="notranslate"/> <meta name="keywords" content="摩熵医药,药融云,生物医药,全球生物医药,摩熵医药数据库,医药数据库,生物医药数据库"/> <meta name="description" content="摩熵医药(原药融云)是全球生物医药产业一站式服务平台，摩熵医药生物医药数据库深度整合了全球生物医药数据、信息、资源等，帮助生物医药产业实现高度信息、数字化，旨在打造生物医药产业数字经济体"/> <meta name="baidu-site-verification" content="codeva-swltDxIOp3" /> <meta name="msvalidate.01" content="5D8080CFE7619A18A486CD68C6A586E2" /> <meta name="google-site-verification" content="0dGPXQuTo72PKJjD9SkddALHCOxuqdE4DYrg7j7u5pY" /> <title>摩熵医药(原药融云)-生物医药全产业链数据服务平台 | 摩熵医药生物医药数据库</title>  <link rel="stylesheet" type="text/css" href="https://at.alicdn.com/t/font_1567116_dcovbumhk8j.css"> <link rel="stylesheet" type="text/css" href="https://at.alicdn.com/t/c/font_2938794_vhg2kzhc0dl.css"> <link rel="stylesheet" type="text/css" href="https://at.alicdn.com/t/c/font_1683998_3si6un8t4lq.css">  <link rel="stylesheet" type="text/css" href="https://at.alicdn.com/t/font_2567648_c15z8q8mh2v.css"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/swiper-bundle.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/swiper-4.5.1.min.css?v=20250403"> <link rel="stylesheet" href="https://g.alicdn.com/de/prismplayer/2.9.18/skins/default/aliplayer-min.css" /> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/base.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/quill.snow.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/wangeditor.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/zdCascader.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/common/component.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/cards/component-card.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/cards/list-card-1.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/cards/list-card-2.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/cards/chart-card.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/dongcha/common/right-card-type1.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/dongcha/common/right-card-type2.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/dongcha/common/right-card-type3.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/errors/no_data.css?v=20250403"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/common/footer.css?v=20250403">  <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/vue-2.6.14.min.js"></script>  <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/swiper-4.5.1.min.js"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/vue-awesome-swiper-3.1.3.min.js"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/swiper-bundle.min.js"></script>  <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/echarts-5.5.0.min.js"></script>  <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/jquery-3.5.1.min.js"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/jquery.pjax-2.0.1.min.js"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/jquery.cookie.js"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/qrcode.min.js"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/bignumber.js"></script>  <script type="text/javascript" charset="utf-8" src="https://g.alicdn.com/de/prismplayer/2.9.18/aliplayer-min.js"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/aliplayer.js"></script>  <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/countUp-2.3.2.min.js"></script>  <script type="text/javascript" src="https://res.wx.qq.com/open/js/jweixin-1.3.2.js"></script>    <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/common/APIconfig.js?v=20250403"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/common/function.js?v=20250403"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/common/request/data.js?v=20250403"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/common/global.js?v=20250403"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/cards/chart.js?v=20250403"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/cards/card.js?v=20250403"></script> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/medical/index.css?v=20250403"> </head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-XZVSHWY2H9"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-XZVSHWY2H9'); </script> <body> <div> <div id="i_cecream">   <div class="layerMouse">  <div class="layerMouse_ad"> <div class="icon chat-btn"> <a> <div class="item_icon item_logo" onclick="toPage('https://www.pharnexcloud.com')"></div> </a> </div> <div class="icon chat-btn"> <a onclick="$('.embed-icon-default').trigger('click');"> <div class="item_icon item_icon1"></div> </a> </div> <div class="icon"> <div class="tips wxapp"> <img src="https://www.pharnexcloud.com/assets/images/common/wxgzh-code.png" alt /> <div> 洞察市场格局 <br />解锁药品研发情报 </div> </div> <div class="item_icon item_icon3"></div> </div> <div class="icon"> <div class="tips tel"> <p>免费客服电话</p> <div class="phone">18983288589</div> </div> <div class="item_icon item_icon2"></div> </div>  </div> <div class="layerMouse_enterprise" onclick="toPage('https://vip.pharnexcloud.com/?auto=1')">试用企业版</div> </div>   <div class="box no-loading" onclick="closeBox()" style="display: none"> <div class="mian" onclick="stop()"> <div class="left"> <img src="https://www.pharnexcloud.com/assets/images/common/no-loding.png" alt /> </div> <div class="right"> <div class="txt">您尚未登陆，请先登录吧</div> <a class="btn" href="https://me.pharnexcloud.com/login/signin?redirect=https://www.pharnexcloud.com">登录</a> </div> </div> </div>  <div class="return-top" onclick="returnTop()"></div> <div class="cover-tips"> <div class="img"></div> <p class="text"></p> </div>   <script> (function() { var _hmt = _hmt || []; var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?69161df66bd66d3aa8e4475e8640ab93"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })() </script> <script> window.location.pathname !== '/' && $('.layerMouse').css('opacity', 1) </script>  <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/common/header.css?v=20250403"> <div id="header"> <div class="top"> <div class="top-content m"> <div class="left"> <img onclick="redirectPage(`https://www.pharnexcloud.com`)" src="https://www.pharnexcloud.com/assets/images/common/logo-green5.png" alt="摩熵医药,生物医药全产业链数据服务平台" class="logo"/> <div class="text">生物医药全产业链数据服务平台</div> </div> <div class="right"> <div class="right-item"> <a href="https://vip.pharnexcloud.com/?from=menhu" target="_blank"> <i class="iconfont icon-daohang-diannao"></i> <span>企业版官网</span> </a> </div> <div class="right-item weapp"> <i class="iconfont icon-a-daohang-shouji"></i> <span>掌上数据</span> <div class="tips wxapp top"> <img src="https://www.pharnexcloud.com/assets/images/common/wxapp-code.jpg" alt=""> <div class="text">打开微信扫一扫</div> </div> </div> <div class="right-item open"> <a href="https://open.bcpmdata.com" rel="nofollow" target="_blank">数据开放平台</a> </div> <div class="right-item matrix" onmouseenter="showMatrix()" onmouseleave="closeMatrix()"> <div class="matrix-btn"> <span>产品矩阵</span> <div class="icon"> <img src="https://www.pharnexcloud.com/assets/images/common/matrix/icon-matrix.png"/> </div> </div> <div class="matrix-box"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/common/product_matrix.css?v=20250403"> <div class="product-matrix" id="product_matrix">  <div class="matrix-popup" onclick="closeMinPopup()"> <div class="matrix-title"> <div class="title">摩熵数科产品矩阵</div> <a class="to-detail" target="_blank" href="https://www.bcpmdata.com">查看详情</a> </div> <div class="matrix-content"> <div class="matrix-item" v-for="(item, index) in product_matrix" :key="index"> <div class="product-class">{{ item.category }}</div> <div class="product-box"> <div class="product-content" v-for="(product, idx) in item.productBox" :key="idx"> <div class="product-info"> <div class="product-name"> <a :href="product.info.url" target="_blank"> <img class="icon" :src="product.info.icon" alt="" > <div :class="['name', product.info.className]">{{ product.info.name }}</div> </a> </div> <div class="product-desc">{{ product.info.desc }}</div> </div> <ul v-if="product.productList" :class="['product-list', product.className]"> <li class="product-item" v-for="(listItem, i) in product.productList" :key="i"> <a :href="listItem.url" :class="[listItem.className]" :target="listItem.className ? '' : '_blank'"> <img class="icon" :src="listItem.icon" alt="" > <div class="name">{{ listItem.name }}</div> </a> <div class="min-popup" onclick="stop()" v-if="listItem.className == 'weapp'"> <div class="min-popup-close" onclick="closeMinPopup()"></div> <div class="popup-title">快速筛选药品，用摩熵药筛</div> <img src="/assets/images/common/matrix/wx-code.png" alt=""> <div class="tips-text">微信扫一扫-立即使用</div> </div> </li> </ul> </div> </div> </div> </div> </div> </div> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/common/product_matrix.js?v=20250403"></script> </div> </div> <div class="right-item login"> <a class="login-btn" rel="nofollow" href="https://me.pharnexcloud.com/login/signin?redirect=https://www.pharnexcloud.com&type=2"> <span>登录  </span>/<span>  免费注册</span> </a> </div> </div>  </div> </div> <div class="header-bar"> <div class="header-content m"> <div class="header-list"> <div class="header-item active"> <div class="item-content"> <a href="https://www.pharnexcloud.com">首页</a> </div> </div> <div class="header-item"> <div class="item-content database"> <a target="_blank" rel="nofollow" href="https://data.pharnexcloud.com/?from=menhu">个人版</a> </div> </div> <div class="header-item"> <div class="item-content db"> <a target="_blank" rel="nofollow" href="https://pharma.bcpmdata.com/?from=menhu">企业版</a> </div> </div> <div class="header-item"> <div class="item-content"> <a target="_blank" rel="nofollow" href="https://edu-pharma.bcpmdata.com/?from=menhu">高校版</a> </div> </div> <div class="header-item"> <div class="item-content hot"> <a target="_blank" href="https://consult.pharnexcloud.com/?from=menhu">摩熵咨询</a> </div> <div class="header-child"> <div class="child0 m"> <div class="left"> <div class="title">咨询服务</div> <ul class="category-list"> <li class="list-item"> <a target="_blank" href="https://consult.pharnexcloud.com/service/item"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-zx-1-1.png"> <span>产品立项评估及管线规划</span><i class="iconfont icon-gengduodanjiantou"></i> </a> </li> <li class="list-item"> <a target="_blank" href="https://consult.pharnexcloud.com/service/data"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-zx-1-2.png"> <span>数据定制服务</span><i class="iconfont icon-gengduodanjiantou"></i> </a> </li> <li class="list-item"> <a target="_blank" href="https://consult.pharnexcloud.com/service/survey"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-zx-1-3.png"> <span>产业/行业调研</span><i class="iconfont icon-gengduodanjiantou"></i> </a> </li> <li class="list-item"> <a target="_blank" href="https://consult.pharnexcloud.com/service/insight"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-zx-1-4.png"> <span>市场洞察咨询服务</span><i class="iconfont icon-gengduodanjiantou"></i> </a> </li> </ul> </div> <div class="right"> <div class="title">资源大厅</div> <ul class="category-list"> <li class="list-item"> <a target="_blank" href="https://consult.pharnexcloud.com/report"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-zx-2-1.png"> <span>报告大厅</span><i class="iconfont icon-gengduodanjiantou"></i> </a> <a target="_blank" href="https://consult.pharnexcloud.com/report"> <div class="item-data">已收录 <span class="count">68492</span> 份</div> </a> </li> <li class="list-item"> <a target="_blank" href="https://consult.pharnexcloud.com/live"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-zx-2-2.png"> <span>摩熵说直播</span><i class="iconfont icon-gengduodanjiantou"></i> </a> <a class="data-news" target="_blank" href="https://consult.pharnexcloud.com/live/detail/80.html"> <div class="item-data"><span class="label">最新</span><span>医药行业中的AI应用与未来趋势</span></div> </a> </li> </ul> </div> <div class="bg"> <a target="_blank" href="https://consult.pharnexcloud.com/medical"> <img src="https://www.pharnexcloud.com/assets/images/medical/bg-header-zx.png" alt=""> </a> </div> </div> </div> </div> <div class="header-item "> <div class="item-content"> <a href="https://www.pharnexcloud.com/zixun">资讯</a> </div> <div class="header-child"> <div class="child1 m"> <div class="left"> <div class="title"><a href="https://www.pharnexcloud.com/zixun/yuanchuang">摩熵原创</a></div> <ul class="category-list"> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/22/7fd10b3af4c6b3224c79814e054468fe.png"> <span><a href="https://www.pharnexcloud.com/zixun/yuanchuang/sd">深度分析</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/22/b1754ab8eeeda1f7d2d65d7592b1ff3e.png"> <span><a href="https://www.pharnexcloud.com/zixun/yuanchuang/gpjx">过评精选</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/22/52d352876b9c67ff7ef02f47335d6d35.png"> <span><a href="https://www.pharnexcloud.com/zixun/yuanchuang/zc">政策法规</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/22/ee5265f05d4c02b5b0aea4eab1a70105.png"> <span><a href="https://www.pharnexcloud.com/zixun/yuanchuang/sdsl">赛道梳理</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/22/5f49fd595e819b87f6190c0abe8a33fc.png"> <span><a href="https://www.pharnexcloud.com/zixun/yuanchuang/trz">投融资</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/22/2212b9f2d0b6817ff610a01e4caf2206.png"> <span><a href="https://www.pharnexcloud.com/zixun/yuanchuang/zcsp">注册审批</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/24/0950140b08d9d615cbe3b94bf3576188.png"> <span><a href="https://www.pharnexcloud.com/zixun/yuanchuang/sx">时讯</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/24/6c1a19b3c1320a22082dc260424a36e8.png"> <span><a href="https://www.pharnexcloud.com/zixun/yuanchuang/kp">科普</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/24/280168212170ce1144ea90e7c3691192.png"> <span><a href="https://www.pharnexcloud.com/zixun/yuanchuang/bg">医药洞见</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/23/8b87c3c06f08d48f53e8a3251a13930b.png"> <span><a href="https://www.pharnexcloud.com/zixun/yuanchuang/hy">会议</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> </ul> </div> <div class="right"> <div class="title"><a href="https://www.pharnexcloud.com/zixun/shiye">摩熵视野</a></div> <ul class="category-list"> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/22/047640c2789fbc174efb4ace3966e554.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/qy">前沿研究</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/22/a06555b3ffd7aa89fdf2d46007f80fa2.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/zb">招标采购</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/22/a0c5a8a2579f257e8f6d5e471a599211.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/gs">公司动态</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/22/228bec2112de117d4121be350e829183.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/cb">财报业绩</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/24/80c64943e94fc84259cd76a39be5fe63.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/lcyj">临床研究</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/24/bf67ec871f3784bfe96ba0d423ca62f9.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/ybdt">医保动态</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/24/fe8b86568711c5657d7b851ce79606c6.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/yfzczc">研发注册政策</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/23/53de4b7f10310bebd2c5c63d36012bb3.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/jybg">交易并购</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/24/950149a8f51006ec4bdb449b77aef418.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/rsbd">人事变动</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/24/9a110a13910c151785a9f6448369d5a1.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/zjgd">专家观点</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/24/3bb3bc3283237c42cf15ba82366d9761.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/sdfx">行业分析</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/24/be2a10fb19e2c59698e390f2a6e21267.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/spdt">审批动态</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202410/24/29cedfae52ccb991f0fd462aef0b1679.png"> <span><a href="https://www.pharnexcloud.com/zixun/shiye/yytrz">医药投融资</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> </ul> </div> </div> </div> </div> <div class="header-item "> <div class="item-content"> <a href="https://www.pharnexcloud.com/data">市场洞察</a> </div> <div class="header-child"> <div class="child2 m"> <ul class="category-list">  <li class="list-item"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-dongcha-2.png"> <span><a href="https://www.pharnexcloud.com/data/zcfg">政策法规</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-dongcha-3.png"> <span><a href="https://www.pharnexcloud.com/data/qynb">上市医药企业年报</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-dongcha-4.png"> <span><a href="https://www.pharnexcloud.com/data/scqy">药品生产企业</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> </ul> </div> </div> </div> <div class="header-item "> <div class="item-content"> <a href="https://www.pharnexcloud.com/data/lcsy">临床进展</a> </div> </div> <div class="header-item "> <div class="item-content"> <a href="https://www.pharnexcloud.com/trz">投融资</a> </div> </div>   <div class="header-item "> <div class="item-content"> <a href="https://www.pharnexcloud.com/about/about">关于我们</a> </div> <div class="header-child"> <div class="child4 m"> <ul class="category-list"> <li class="list-item"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-about-1.png"> <span><a href="https://www.pharnexcloud.com/about/about">公司介绍</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-about-2.png"> <span><a href="https://www.pharnexcloud.com/join">加入我们</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-about-3.png"> <span><a href="https://www.pharnexcloud.com/about/relate">联系我们</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-about-4.png"> <span><a href="https://www.pharnexcloud.com/about/product">产品与服务</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> <li class="list-item"> <img class="icon" src="https://www.pharnexcloud.com/assets/images/medical/header-icon/icon-about-5.png"> <span><a href="https://www.pharnexcloud.com/about/team">团队介绍</a></span><i class="iconfont icon-gengduodanjiantou"></i> </li> </ul> </div> </div> </div> </div> <div class="header-input" onclick="headerSearchShow(this)"> <span class="text">请输入关键词</span><i class="iconfont iconsousuo"></i> <div class="input-content"> <input class="input header-search" type="text" placeholder="请输入关键词"> <div class="search-btn" onclick="handleHeaderSearch()"><i class="iconfont iconsousuo"></i></div> <div class="clear-btn" onclick="headerSearchClose(this)"><i class="iconfont icon-guanbianniu"></i></div> <div class="hot-search header-history"> <div class="name">历史搜索<span class="close iconfont iconshanchu1" onmousedown="clearHeaderHistory(null)"></span></div> <ul class="history-list"></ul> </div> <div class="hot-search"> <div class="name">热门搜索</div> <ul class="hot-list"> <li onclick="setHeaderHistory(`GLP-1`)" class="list-item">GLP-1</li> </ul> </div> </div> </div> </div> </div> </div> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/common/header.js?v=20250403"></script>   <div id="home" class="home"> <div class="top"> <div class="video"> <video class="video-content" loop autoplay muted src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/files/menhu.mp4" /> </div> <div class="top-content m"> <h1 class="name"><span class="blue">摩熵医药</span> <span>生物医药全产业链数据服务平台</span></h1> <p class="text">专注医药产业数据解决方案</p> <div class="search-input"> <div> <input class="data" ref="input" type="text" autocomplete="off" placeholder="通过搜索即可访问相关药物、临床试验、适应症、研发数据等" name="https://www.pharnexcloud.com/" /> <span class="clear" onmousedown="clearInput()"></span> </div> <div class="history"> <ul class="historyTxt"></ul> </div> <div class="search-btn" onclick="handleSearch()"> <i class="iconfont iconsousuo"></i> 立即搜索 </div> </div>  <div class="hot-search"> <span class="hot-title">热门搜索：</span> <span class="hot-search-item ishome"> <span onclick="sethistory('BCMA')">BCMA</span> </span> <span class="hot-search-item ishome"> <span onclick="sethistory('恒瑞')">恒瑞</span> </span> <span class="hot-search-item ishome"> <span onclick="sethistory('mRNA')">mRNA</span> </span> <span class="hot-search-item ishome"> <span onclick="sethistory('右美托咪定')">右美托咪定</span> </span> <span class="hot-search-item ishome"> <span onclick="sethistory('艾司氯胺酮')">艾司氯胺酮</span> </span> <span class="hot-search-item ishome"> <span onclick="sethistory('富马酸伏诺拉生片')">富马酸伏诺拉生片</span> </span> </div> </div> <div class="top-data"> <div class="data-content m"> <div class="data-item"> <p class="data-num" id="numItem1">0</p> <p class="data-name">新药研发</p> </div> <div class="data-item"> <p class="data-num" id="numItem2">0</p> <p class="data-name">临床试验</p> </div> <div class="data-item"> <p class="data-num" id="numItem3">0</p> <p class="data-name">靶点</p> </div> <div class="data-item"> <p class="data-num" id="numItem4">0</p> <p class="data-name">适应症</p> </div> <div class="data-item"> <p class="data-num" id="numItem5">0</p> <p class="data-name">医药企业</p> </div> </div> </div> </div> <div class="container container1 m"> <div class="left"> <div class="left-title"> <div class="hot-tag"> <p>HOT</p> <p>热门</p> </div> <h2 class="title-name">资讯</h2> <div class="more"><a target="_blank" href="https://www.pharnexcloud.com/zixun">更多<i class="icon iconfont icon-gengduojiantou"></i></a></div> </div> <div class="hot-content-1"> <div class="hot-swiper" id="newsSwiperOption"> <swiper :options="newsSwiperOption" v-model="index" ref="newsSwiperOption"> <swiper-slide> <div class="news-item" onclick="targetBlank(this)"> <div class="img" style="background-image: url(https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202504/03/3d21b6c536a741ce9fea39617a0d2022.png);"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202504/03/3d21b6c536a741ce9fea39617a0d2022.png" alt="摩熵数科助力成都市新都区卫健系统医院数字化培训，共探医疗大数据与AI未来"> </div> <p class="news-title"><a onclick="return false" target="_blank" href="https://www.pharnexcloud.com/zixun/sx_42194" title="摩熵数科助力成都市新都区卫健系统医院数字化培训，共探医疗大数据与AI未来">摩熵数科助力成都市新都区卫健系统医院数字化培训，共探医疗大数据与AI未来</a></p> </div> </swiper-slide> <swiper-slide> <div class="news-item" onclick="targetBlank(this)"> <div class="img" style="background-image: url(https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202502/28/b70a8b2def2e58dfccdb6b0df530deb4.png);"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202502/28/b70a8b2def2e58dfccdb6b0df530deb4.png" alt="重磅升级！摩熵医药接入DeepSeek，全新推出三大AI服务功能"> </div> <p class="news-title"><a onclick="return false" target="_blank" href="https://www.pharnexcloud.com/zixun/sx_37892" title="重磅升级！摩熵医药接入DeepSeek，全新推出三大AI服务功能">重磅升级！摩熵医药接入DeepSeek，全新推出三大AI服务功能</a></p> </div> </swiper-slide> <swiper-slide> <div class="news-item" onclick="targetBlank(this)"> <div class="img" style="background-image: url(https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202502/14/f67628957e1359c2134a15d013e81baf.png);"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202502/14/f67628957e1359c2134a15d013e81baf.png" alt="全国医院销售数据查询"> </div> <p class="news-title"><a onclick="return false" target="_blank" href="https://vip.pharnexcloud.com/database/yysale?auto=1&from=menhugundong" title="全国医院销售数据查询">全国医院销售数据查询</a></p> </div> </swiper-slide> <swiper-slide> <div class="news-item" onclick="targetBlank(this)"> <div class="img" style="background-image: url(https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202410/22/704869c8373656cef84d4d5acae25d88.jpg);"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202410/22/704869c8373656cef84d4d5acae25d88.jpg" alt="乳腺癌药物——市场研究专题报告"> </div> <p class="news-title"><a onclick="return false" target="_blank" href="https://www.pharnexcloud.com/zixun/sd_36573" title="乳腺癌药物——市场研究专题报告">乳腺癌药物——市场研究专题报告</a></p> </div> </swiper-slide> <swiper-slide> <div class="news-item" onclick="targetBlank(this)"> <div class="img" style="background-image: url(https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202502/14/634e89e2e3fc1857c2a5712e408f98c8.png);"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202502/14/634e89e2e3fc1857c2a5712e408f98c8.png" alt="医药市场研究分析专题"> </div> <p class="news-title"><a onclick="return false" target="_blank" href="https://www.pharnexcloud.com/zhuanti/6" title="医药市场研究分析专题">医药市场研究分析专题</a></p> </div> </swiper-slide> <swiper-slide> <div class="news-item" onclick="targetBlank(this)"> <div class="img" style="background-image: url(https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202410/22/94b17bc4412f4e3e0c7e1205a0e43df8.jpg);"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202410/22/94b17bc4412f4e3e0c7e1205a0e43df8.jpg" alt="2022年全球CRO公司排名TOP10！"> </div> <p class="news-title"><a onclick="return false" target="_blank" href="https://www.pharnexcloud.com/zixun/sd_5908" title="2022年全球CRO公司排名TOP10！">2022年全球CRO公司排名TOP10！</a></p> </div> </swiper-slide> <swiper-slide> <div class="news-item" onclick="targetBlank(this)"> <div class="img" style="background-image: url(https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202410/23/bddd9b3152f4e73b144b87533c075c87.jpg);"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202410/23/bddd9b3152f4e73b144b87533c075c87.jpg" alt="浅析BCS分类"> </div> <p class="news-title"><a onclick="return false" target="_blank" href="https://www.pharnexcloud.com/zixun/zc_1790" title="浅析BCS分类">浅析BCS分类</a></p> </div> </swiper-slide> <swiper-slide> <div class="news-item" onclick="targetBlank(this)"> <div class="img" style="background-image: url(https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202410/22/ee3fc97c78b5540c23a5390a8f38fdb9.jpg);"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/news_banners/202410/22/ee3fc97c78b5540c23a5390a8f38fdb9.jpg" alt="700亿市场！乙肝新药进展更新，东阳光「利托那韦」获批临床"> </div> <p class="news-title"><a onclick="return false" target="_blank" href="https://www.pharnexcloud.com/zixun/sx_5786" title="700亿市场！乙肝新药进展更新，东阳光「利托那韦」获批临床">700亿市场！乙肝新药进展更新，东阳光「利托那韦」获批临床</a></p> </div> </swiper-slide> <div class="swiper-pagination" slot="pagination"></div> </swiper> </div> <div class="content-right"> <div class="news-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/07/b99ac4e1b2077d637c3608ffd8ea0d02.png" alt="流行病学数据库：赋能医药企业，优化研发决策！"> </div> <p class="news-title"><a onclick="return false" class="item-title" href="/zixun/sx_26959" target="_blank" title="流行病学数据库：赋能医药企业，优化研发决策！">流行病学数据库：赋能医药企业，优化研发决策！</a></p> </div> <div class="news-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202410/23/d76481c78e1d7dc22ef37b8ce2d4f80c.png" alt="2020免费版《中国药典》在线查询官网入口|中国药典电子版"> </div> <p class="news-title"><a onclick="return false" class="item-title" href="/zixun/kp_7349" target="_blank" title="2020免费版《中国药典》在线查询官网入口|中国药典电子版">2020免费版《中国药典》在线查询官网入口|中国药典电子版</a></p> </div> </div> </div> <div class="hot-content-2"> <div class="left"> <div class="news-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/07/29d257a20c830ff99835bf87481676f2.png" alt="摩熵医药【网上药店销售数据库】全面上线！销售数据全渠道覆盖，精准洞察市场趋势！"> </div> <p class="news-title"><a onclick="return false" class="item-title" href="/zixun/sx_8649" target="_blank" title="摩熵医药【网上药店销售数据库】全面上线！销售数据全渠道覆盖，精准洞察市场趋势！">摩熵医药【网上药店销售数据库】全面上线！销售数据全渠道覆盖，精准洞察市场趋势！</a></p> </div> <button class="more"> <a target="_blank" href="https://www.pharnexcloud.com/zixun">MORE+</a> </button> </div> <div class="right"> <ul class="news-list"> <li class="news-item" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" class="item-title" href="/zixun/sx_37892" target="_blank" title="重磅升级！摩熵医药接入DeepSeek，全新推出三大AI服务功能">重磅升级！摩熵医药接入DeepSeek，全新推出三大AI服务功能</a></p> <span class="time">2025-02-20</span> </li> <li class="news-item" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" class="item-title" href="/zixun/sd_35582" target="_blank" title="淋巴瘤药物市场研究专题报告">淋巴瘤药物市场研究专题报告</a></p> <span class="time">2025-01-08</span> </li> <li class="news-item" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" class="item-title" href="/zixun/sd_31117" target="_blank" title="2023年原料药企业排行榜：新和成、国邦医药等企业综合实力大揭秘">2023年原料药企业排行榜：新和成、国邦医药等企业综合实力大揭秘</a></p> <span class="time">2024-11-26</span> </li> <li class="news-item" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" class="item-title" href="/zixun/sd_36573" target="_blank" title="乳腺癌药物——市场研究专题报告">乳腺癌药物——市场研究专题报告</a></p> <span class="time">2025-01-16</span> </li> <li class="news-item" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" class="item-title" href="/zixun/sd_33273" target="_blank" title="2024年中国糖尿病临床治疗需求及治疗进展分析">2024年中国糖尿病临床治疗需求及治疗进展分析</a></p> <span class="time">2024-12-17</span> </li> <li class="news-item" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" class="item-title" href="/zixun/sdsl_37510" target="_blank" title="2024年上市CGT公司最新研发进展">2024年上市CGT公司最新研发进展</a></p> <span class="time">2025-02-07</span> </li> <li class="news-item" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" class="item-title" href="/zixun/sd_37006" target="_blank" title="2024年中国合成生物产业链中下游企业分析：技术突破与市场布局">2024年中国合成生物产业链中下游企业分析：技术突破与市场布局</a></p> <span class="time">2025-01-22</span> </li> </ul> </div> </div> </div> <div class="right"> <div class="right-box"> <div class="tab"> <div data-id="box-1" data-category="qy" class="tab-item tab-text active">前沿研究</div> <div data-id="box-2" data-category="lcyj" class="tab-item tab-text">临床研究</div> <div data-id="box-3" data-category="jybg" class="tab-item tab-text">交易并购</div> <div class="tab-item more"> <span class="icon iconfont icon-gengduoshuangjiantou"></span> </div> </div> <ul class="right-content box-1 active-box"> <li class="news-item" onclick="targetBlank(this)"> <div class="img"> <div class="default-img"> <div class="news-title">e药房｜每日一粒就能调节血脂！这款全新一代非诺贝特类药物有何独特之处？</div> </div> </div> <div class="info"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42540" title="e药房｜每日一粒就能调节血脂！这款全新一代非诺贝特类药物有何独特之处？">e药房｜每日一粒就能调节血脂！这款全新一代非诺贝特类药物有何独特之处？</a></p> <span class="time">2025-04-07</span> </div> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42541" title="APSB | 吴寿荣/江启慧（Vivi Kasim）团队揭示肿瘤细胞通过增强mRNA稳定性抵御铁死亡的新机制">APSB | 吴寿荣/江启慧（Vivi Kasim）团队揭示肿瘤细胞通过增强mRNA稳定性抵御铁死亡的新机制</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42542" title="Autophagy｜酵母细胞中营养感应与细胞生长调控的新机制">Autophagy｜酵母细胞中营养感应与细胞生长调控的新机制</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42543" title="Cell | 通过小分子诱导组织低氧状态可逆转神经损伤">Cell | 通过小分子诱导组织低氧状态可逆转神经损伤</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42544" title="Alzheimer's & Dementia丨赖东梅团队揭示早发性卵巢功能不全/卵巢早衰女性的早期痴呆相关脑结构改变">Alzheimer's & Dementia丨赖东梅团队揭示早发性卵巢功能不全/卵巢早衰女性的早期痴呆相关脑结构改变</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42545" title="Cancer Discovery丨内皮细胞中PTEN的体细胞单亲二倍体导致PTEN错构瘤肿瘤综合征患者的血管畸形">Cancer Discovery丨内皮细胞中PTEN的体细胞单亲二倍体导致PTEN错构瘤肿瘤综合征患者的血管畸形</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42546" title="JBC丨人源tau蛋白在急性高血糖情况下促进有氧糖酵解">JBC丨人源tau蛋白在急性高血糖情况下促进有氧糖酵解</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42547" title="疫苗新突破：一文读懂自我扩增 RNA（saRNA）疫苗">疫苗新突破：一文读懂自我扩增 RNA（saRNA）疫苗</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42548" title="一种新型乳房植入物——聚己内酯">一种新型乳房植入物——聚己内酯</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42549" title="ADC药物创新技术策略进展">ADC药物创新技术策略进展</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42550" title="Cancer Cell | 上海药物所合作绘制无功能性胰腺神经内分泌瘤多组学分子图谱">Cancer Cell | 上海药物所合作绘制无功能性胰腺神经内分泌瘤多组学分子图谱</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" href="/zixun/shiye/qy_42551" title="NEW PAI | 奥利司他开环差向异构体">NEW PAI | 奥利司他开环差向异构体</a></p> <span class="time">2025-04-07</span> </li> </ul> <ul class="right-content box-2"> <li class="news-item" onclick="targetBlank(this)"> <div class="img"> <div class="default-img"> <div class="news-title">瑞博生物全球首个靶向FXI的抗血栓siRNA药物完成IIa期临床试验患者入组</div> </div> </div> <div class="info"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42579" title="瑞博生物全球首个靶向FXI的抗血栓siRNA药物完成IIa期临床试验患者入组">瑞博生物全球首个靶向FXI的抗血栓siRNA药物完成IIa期临床试验患者入组</a></p> <span class="time">2025-04-07</span> </div> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42580" title="致病蛋白降幅超90%！口服LRRK2-PROTAC降解剂首次人体研究结果公布">致病蛋白降幅超90%！口服LRRK2-PROTAC降解剂首次人体研究结果公布</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42581" title="全球首发！康诺亚IL-4Rα抗体治疗季节性过敏性鼻炎III期研究数据发表于Nature Medicine">全球首发！康诺亚IL-4Rα抗体治疗季节性过敏性鼻炎III期研究数据发表于Nature Medicine</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42582" title="YSCH-01在上海市肺科医院完成首例CT引导下经皮直接肺穿刺给药">YSCH-01在上海市肺科医院完成首例CT引导下经皮直接肺穿刺给药</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42583" title="首季连发3项肝母细胞瘤重磅研究成果，上海儿童医学中心以91.9%的5年总生存率刷新诊疗纪录">首季连发3项肝母细胞瘤重磅研究成果，上海儿童医学中心以91.9%的5年总生存率刷新诊疗纪录</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42584" title="凡恩世制药双抗peluntamig（PT217）II期联合治疗临床试验申请获CDE批准">凡恩世制药双抗peluntamig（PT217）II期联合治疗临床试验申请获CDE批准</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42585" title="ACC.25 | 高危PCI患者完成DAPT后，长期单药治疗氯吡格雷优于阿司匹林">ACC.25 | 高危PCI患者完成DAPT后，长期单药治疗氯吡格雷优于阿司匹林</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42586" title="新华医院顺利完成PKU基因治疗高剂量组全部受试者给药">新华医院顺利完成PKU基因治疗高剂量组全部受试者给药</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42587" title="帕金森治疗领域全球首个进入新药注册临床阶段的基于iPSC及化学诱导的通用型细胞治疗产品启动II期临床">帕金森治疗领域全球首个进入新药注册临床阶段的基于iPSC及化学诱导的通用型细胞治疗产品启动II期临床</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42588" title="花瓣生物：首款国产琼脂糖注射凝胶已进入临床，临床初步反馈稳定">花瓣生物：首款国产琼脂糖注射凝胶已进入临床，临床初步反馈稳定</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42522" title="穿越血脑屏障，蛋白降解剂首个临床试验结果公布；罗氏新一代阿尔茨海默病疗法今年步入3期临床…… | 一周盘点">穿越血脑屏障，蛋白降解剂首个临床试验结果公布；罗氏新一代阿尔茨海默病疗法今年步入3期临床…… | 一周盘点</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/lcyj_42523" title="正大天晴：EGFR/c-Met 靶向双抗 ADC 申报临床">正大天晴：EGFR/c-Met 靶向双抗 ADC 申报临床</a></p> <span class="time">2025-04-07</span> </li> </ul> <ul class="right-content box-3"> <li class="news-item" onclick="targetBlank(this)"> <div class="img"> <div class="default-img"> <div class="news-title">27亿美元！GSK与韩国一家Biotech达成全球许可协议</div> </div> </div> <div class="info"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42626" title="27亿美元！GSK与韩国一家Biotech达成全球许可协议">27亿美元！GSK与韩国一家Biotech达成全球许可协议</a></p> <span class="time">2025-04-07</span> </div> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42627" title="高达20.75亿英镑！GSK达成一项针对神经退行性疾病的开发合作">高达20.75亿英镑！GSK达成一项针对神经退行性疾病的开发合作</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42628" title="20.75亿英镑！GSK与ABL Bio合作开发神经退行性疾病创新疗法">20.75亿英镑！GSK与ABL Bio合作开发神经退行性疾病创新疗法</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42629" title="20.75亿英镑！ GSK 引进 Grabody-B 脑递送平台，共同开发神经退行性疾病新药">20.75亿英镑！ GSK 引进 Grabody-B 脑递送平台，共同开发神经退行性疾病新药</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42630" title="14.18 亿美元！礼来重金押注基因疗法，可穿透血脑屏障">14.18 亿美元！礼来重金押注基因疗法，可穿透血脑屏障</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42631" title="27亿美元！GSK与ABL Bio达成全球许可协议，开发CNS新药">27亿美元！GSK与ABL Bio达成全球许可协议，开发CNS新药</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42632" title="2025年3月中国医药BD交易盘点">2025年3月中国医药BD交易盘点</a></p> <span class="time">2025-04-07</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42465" title="抛售生物类似药...君实生物合作伙伴Coherus回购1.7亿美元票据">抛售生物类似药...君实生物合作伙伴Coherus回购1.7亿美元票据</a></p> <span class="time">2025-04-05</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42423" title="4.65亿美元！赛诺菲重金押注蛋白降解技术：自免领域迎来“不可成药靶点”破局者">4.65亿美元！赛诺菲重金押注蛋白降解技术：自免领域迎来“不可成药靶点”破局者</a></p> <span class="time">2025-04-05</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42409" title="14.18亿美元！礼来与Sangamo达成授权许可协议">14.18亿美元！礼来与Sangamo达成授权许可协议</a></p> <span class="time">2025-04-04</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42410" title="礼来出手14亿美元再度拯救陷入困境的Sangamo！">礼来出手14亿美元再度拯救陷入困境的Sangamo！</a></p> <span class="time">2025-04-04</span> </li> <li class="news-item clearfix" onclick="targetBlank(this)"> <p class="news-title"><a onclick="return false" target="_blank" class="item-title" href="/zixun/shiye/jybg_42326" title="生物科技界的收购风云：有人拒绝，有人拥抱">生物科技界的收购风云：有人拒绝，有人拥抱</a></p> <span class="time">2025-04-03</span> </li> </ul> </div> </div> </div> <div class="images m"> <a onclick="advertAddClick(1)" target="_blank" rel="nofollow" href="https://vip.pharnexcloud.com/database/yysale?auto=1&from=menhu-zhongjianguanggao1" ><img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/ad_images/202410/22/0f7b28dbd6c529fc479f34b978ee0496.jpg" alt="全国医院销售数据"></a> </div> <div class="container container2 m"> <div class="left"> <div class="left-title"> <ul class="tabs"> <li data-id="content-1" class="tab-item active">最新报告</li> <li data-id="content-2" data-cate="1" class="tab-item">深度报告</li> <li data-id="content-3" data-cate="2" class="tab-item">医药观察周报</li> <li data-id="content-4" data-cate="3" class="tab-item">医药观察月报</li> <li data-id="content-5" data-cate="4" class="tab-item">定制化报告</li> </ul> <div class="more"><a target="_blank" href="https://consult.pharnexcloud.com/report">更多<i class="icon iconfont icon-gengduojiantou"></i></a></div> </div> <ul class="report-content content-1 active-content"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-2.png" alt="2024年医保谈判及市场分析报告"> <div class="report-name item-2">2024年医保谈判及市场分析报告</div> <div class="tag color-1">深度报告</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/68532.html">2024年医保谈判及市场分析报告</a></div> <div class="desc">本报告结合市场数据分析，探讨医保谈判对医药企业、医疗市场格局以及患者用药可及性和负担的影响，揭示医保谈判在推动医药行业创新发展、促进医疗资源合理配置中的关键作用，旨在为医药企业及相关从业者提供全面且深入的参考依据。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>34页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>医保谈判</span> <span>医保品种</span> <span>医保目录</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-1.png" alt="摩熵咨询医药行业观察周报（2025.03.24-2025.03.30)"> <div class="report-name item-1">摩熵咨询医药行业观察周报（2025.03.24-2025.03.30)</div> <div class="tag color-2">医药观察周报</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/68531.html">摩熵咨询医药行业观察周报（2025.03.24-2025.03.30)</a></div> <div class="desc">1.1总体概况根据摩熵医药数据库统计，2025.03.24-2025.03.30期间共有69个创新药/改良型新药临床申请/上市申请获国家药品监督管理局药品审评中心（CDE）承办（按受理号统计，不含补充申请）。其中国产药品受理号41个，进口药品受理号28个。本周共计64款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药33款，生物药30款，中药1款。其中值得注意的有：（1）HDM-30193月25日，CDE官网公示：华东医药的HDM-3019获得临床试验默示许可，用于治疗类风湿关节炎。公开资料显示，HDM-3019是靶向OX40L和TNFα的双特异性抗体，参与调节炎症细胞因子，促进T细胞和浆细胞分化，以及自身抗体产生，维持免疫稳态平衡。（2）BBM-A101注射液3月27日，CDE官网公示：信念医药的BBM-A101注射液获得临床试验默示许可，用于治疗中度膝骨关节炎。公开资料显示，BBM-A101注射液利用AAV载体将人源抗炎蛋白基因递送到患者膝关节持续表达，进而有望缓解关节腔内炎症，减轻膝骨关节炎患者的疼痛并改善膝关节功能，从而延缓疾病进程，最终改善膝骨关节炎患者的治疗结局。该产品有望实现“一次给药、长期有效”的膝骨关节炎治疗。（3）Eneboparatide注射液3月27日，CDE官网公示：阿斯利康（AstraZeneca）的Eneboparatide注射液获得临床试验默示许可，用于治疗慢性甲状旁腺功能减退症(cHP)。公开资料显示，Eneboparatide注射液是一种甲状旁腺激素受体1（PTHR1）激动剂，它通过与PTHR1的特定构象结合，恢复PTH的功能，从而管理HypoPT患者的症状，同时保留肾功能和骨骼健康，旨在满足甲状旁腺功能减退症的治疗目标。该产品已获得美国FDA授予的快速通道资格和孤儿药资格，并获得欧洲药品管理局的孤儿药资格。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-30</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>21页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>创新药/改良型新药</span> <span>仿制药</span> <span>行业政策法规</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-3.png" alt="中国AI医疗健康企业创新发展百强榜单"> <div class="report-name item-3">中国AI医疗健康企业创新发展百强榜单</div> <div class="tag color-2">深度报告</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/68530.html">中国AI医疗健康企业创新发展百强榜单</a></div> <div class="desc">AI在医疗健康领域的应用经过多年发展，技术积累越发成熟，应用场景日益丰富。本报告详细解析了AI在医疗健康领域的发展历程、应用场景及市场前景，还发布了2024年中国AI医疗健康企业百强榜单，分为第一、第二、第三梯队，涵盖迈瑞医疗、科大讯飞、联影医疗等知名企业。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-27</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>26页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>重点企业</span> <span>市场洞察</span> <span>AI医疗</span> </div> </div> </div> </li> </ul> <ul class="report-content content-2"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-2.png" alt="2024年医保谈判及市场分析报告"> <div class="report-name item-2">2024年医保谈判及市场分析报告</div> <div class="tag color-1">深度报告</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/68532.html">2024年医保谈判及市场分析报告</a></div> <div class="desc">本报告结合市场数据分析，探讨医保谈判对医药企业、医疗市场格局以及患者用药可及性和负担的影响，揭示医保谈判在推动医药行业创新发展、促进医疗资源合理配置中的关键作用，旨在为医药企业及相关从业者提供全面且深入的参考依据。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>34页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>医保谈判</span> <span>医保品种</span> <span>医保目录</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-3.png" alt="中国AI医疗健康企业创新发展百强榜单"> <div class="report-name item-3">中国AI医疗健康企业创新发展百强榜单</div> <div class="tag color-1">深度报告</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/68530.html">中国AI医疗健康企业创新发展百强榜单</a></div> <div class="desc">AI在医疗健康领域的应用经过多年发展，技术积累越发成熟，应用场景日益丰富。本报告详细解析了AI在医疗健康领域的发展历程、应用场景及市场前景，还发布了2024年中国AI医疗健康企业百强榜单，分为第一、第二、第三梯队，涵盖迈瑞医疗、科大讯飞、联影医疗等知名企业。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-27</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>26页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>重点企业</span> <span>市场洞察</span> <span>AI医疗</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-3.png" alt="2024年中国1类新药靶点白皮书"> <div class="report-name item-3">2024年中国1类新药靶点白皮书</div> <div class="tag color-2">深度报告</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/68528.html">2024年中国1类新药靶点白皮书</a></div> <div class="desc">2019-2024年期间，我国1类新药受理数量逐步提高，2022年出现小幅度下降，2023年大幅回升，2024年持续攀升，同比上升4.1%。从药品类型受理号来看，2024年化学药1175个，生物制品817个。2019-2024年期间，我国1类新药涉及靶点数量整体呈上升趋势，其中2022年较2021年有所下降，但与2020年相比仍有增长，2023年新药涉及靶点数量为连续6年内最高，达375个，2024年靶点数量总计达342个，同比下降8.8%。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-21</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>30页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>1类新药</span> <span>热门靶点</span> <span>中国新靶点</span> </div> </div> </div> </li> </ul> <ul class="report-content content-3"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-1.png" alt="摩熵咨询医药行业观察周报（2025.03.24-2025.03.30)"> <div class="report-name item-1">摩熵咨询医药行业观察周报（2025.03.24-2025.03.30)</div> <div class="tag color-2">医药观察周报</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/68531.html">摩熵咨询医药行业观察周报（2025.03.24-2025.03.30)</a></div> <div class="desc">1.1总体概况根据摩熵医药数据库统计，2025.03.24-2025.03.30期间共有69个创新药/改良型新药临床申请/上市申请获国家药品监督管理局药品审评中心（CDE）承办（按受理号统计，不含补充申请）。其中国产药品受理号41个，进口药品受理号28个。本周共计64款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药33款，生物药30款，中药1款。其中值得注意的有：（1）HDM-30193月25日，CDE官网公示：华东医药的HDM-3019获得临床试验默示许可，用于治疗类风湿关节炎。公开资料显示，HDM-3019是靶向OX40L和TNFα的双特异性抗体，参与调节炎症细胞因子，促进T细胞和浆细胞分化，以及自身抗体产生，维持免疫稳态平衡。（2）BBM-A101注射液3月27日，CDE官网公示：信念医药的BBM-A101注射液获得临床试验默示许可，用于治疗中度膝骨关节炎。公开资料显示，BBM-A101注射液利用AAV载体将人源抗炎蛋白基因递送到患者膝关节持续表达，进而有望缓解关节腔内炎症，减轻膝骨关节炎患者的疼痛并改善膝关节功能，从而延缓疾病进程，最终改善膝骨关节炎患者的治疗结局。该产品有望实现“一次给药、长期有效”的膝骨关节炎治疗。（3）Eneboparatide注射液3月27日，CDE官网公示：阿斯利康（AstraZeneca）的Eneboparatide注射液获得临床试验默示许可，用于治疗慢性甲状旁腺功能减退症(cHP)。公开资料显示，Eneboparatide注射液是一种甲状旁腺激素受体1（PTHR1）激动剂，它通过与PTHR1的特定构象结合，恢复PTH的功能，从而管理HypoPT患者的症状，同时保留肾功能和骨骼健康，旨在满足甲状旁腺功能减退症的治疗目标。该产品已获得美国FDA授予的快速通道资格和孤儿药资格，并获得欧洲药品管理局的孤儿药资格。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-30</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>21页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>创新药/改良型新药</span> <span>仿制药</span> <span>行业政策法规</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-3.png" alt="摩熵咨询医药行业观察周报（2025.03.17-2025.03.23)"> <div class="report-name item-3">摩熵咨询医药行业观察周报（2025.03.17-2025.03.23)</div> <div class="tag color-1">医药观察周报</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/68529.html">摩熵咨询医药行业观察周报（2025.03.17-2025.03.23)</a></div> <div class="desc">根据摩熵医药数据库统计，2025.03.17-2025.03.23期间共有56个创新药/改良型新药临床申请/上市申请获国家药品监督管理局药品审评中心（CDE）承办（按受理号统计，不含补充申请）。其中国产药品受理号40个，进口药品受理号16个。本周共计58款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药24款，生物药30款，中药4款。其中值得注意的有：（1）SENL-103自体T细胞注射液3月18日，CDE官网公示：森朗生物的SENL-103自体T细胞注射液获得临床试验默示许可，用于治疗复发或难治性多发性骨髓瘤（RRMM）。公开资料显示，SENL-103自体T细胞注射液是一款靶向BCMA的CAR-T细胞治疗药物，可以通过基因工程T细胞“定向狙击”肿瘤，精准作用于多发性骨髓瘤细胞中高表达的BCMA，进而发挥药效。（2）DNTH-103注射液3月19日，CDE官网公示：元羿生物的DNTH-103注射液获得临床试验默示许可，用于治疗慢性炎性脱髓鞘性多发性神经根神经病（Chronic inflammatory demyelinating polyneuropathy,CIDP）。公开资料显示，DNTH-103注射液是元羿生物从Dianthus Therapeutics引进的一种高效的活性C1s抑制剂单克隆抗体产品，通过选择性抑制活性形式的C1s蛋白（一个经过临床验证的补体靶点）来靶向经典途径。（3）ETS-006片3月20日，CDE官网公示：奕拓医药的ETS-006片获得临床试验默示许可，用于治疗实体瘤。公开资料显示，ETS-006片是奕拓医药自主研发的口服、高活性和高选择性的YAP/TEAD蛋白-蛋白相互作用（PPI）抑制剂。它能够高效抑制YAP转录因子的液-液相分离，从而抑制YAP的转录活性。本周共2款新药获批上市，即硫酸艾玛昔替尼片和氢溴酸他泽司他片。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-23</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>23页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>创新药/改良型新药</span> <span>仿制药</span> <span>行业政策法规</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-1.png" alt="摩熵咨询医药行业观察周报（2025.03.10-2025.03.16)"> <div class="report-name item-1">摩熵咨询医药行业观察周报（2025.03.10-2025.03.16)</div> <div class="tag color-3">医药观察周报</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/68527.html">摩熵咨询医药行业观察周报（2025.03.10-2025.03.16)</a></div> <div class="desc">1.总体概况根据摩熵医药数据库统计，2025.03.10-2025.03.16期间共有66个创新药/改良型新药临床申请/上市申请获国家药品监督管理局药品审评中心（CDE）承办（按受理号统计，不含补充申请）。其中国产药品受理号47个，进口药品受理号19个。本周共计91款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药51款，生物药36款，中药4款。其中值得注意的有：（1）BMS-986489注射液3月10日，CDE官网公示：百时美施贵宝的BMS-986489注射液获得临床试验默示许可，用于治疗小细胞肺癌（SCLC）患者。公开资料显示，BMS-986489注射液是一种新型的、与FucGM1特异性结合的全人源IgG1抗体。在临床前研究中，该产品显示出对表达FucGM1的肿瘤细胞系的抗体依赖性细胞毒性(ADCC)。在补体依赖性细胞毒性(CDC)和抗体依赖性细胞吞噬(ADCP)实验中也观察到该产品介导的肿瘤细胞杀伤。当BMS-986012与抗PD-1抗体联合使用时，治疗效果明显改善。（2）AD-108注射液3月12日，CDE官网公示：艾迪药业的AD-108注射液获得临床试验默示许可，用于改善急性缺血性脑卒中所致的神经功能缺损。公开资料显示，AD-108注射液活性成分为人尿激肽原酶，即组织型激肽释放酶-1（KLK-1），是由肾脏分泌的一种丝氨酸蛋白酶，通过激肽释放酶-激肽系统（KKS）在人体内发挥生物学效应，其与肾素-血管紧张素系统（RAS）之间相互作用和平衡，共同维持血液循环系统的稳定和功能。（3）CMS-D003胶囊3月12日，CDE官网公示：康哲药业的CMS-D003胶囊获得临床试验默示许可，用于治疗成人梗阻性肥厚型心肌病。公开资料显示，CMS-D003胶囊是一种小分子心肌肌球蛋白抑制剂，可通过靶向抑制心肌肌球蛋白三磷酸腺苷（ATP）酶，抑制肌球蛋白-肌动蛋白相互作用，减少肌丝滑动，抑制心肌的过度收缩，改善心脏的舒张功能障碍，从而缓解患者的临床症状。本周共3款新药获批上市，即埃纳妥单抗注射液、利生奇珠单抗注射液和伊那利塞片。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-16</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>26页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>创新药/改良型新药</span> <span>仿制药</span> <span>行业政策法规</span> </div> </div> </div> </li> </ul> <ul class="report-content content-4"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-2.png" alt="2025年2月全球在研新药月报"> <div class="report-name item-2">2025年2月全球在研新药月报</div> <div class="tag color-1">医药观察月报</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/68524.html">2025年2月全球在研新药月报</a></div> <div class="desc">根据摩熵医药数据库统计，2025年2月共有144款新药获批临床（共计229个受理号），较上个月增加了21款，其中包括65款化药，76款生物制品，3款中药。本月获批临床受理号数量最多的新药为抗肿瘤药和免疫机能调节药物，有130个，占比为57%，消化系统与代谢药物获批数量也比较多，有18个。获批剂型主要为注射剂与片剂，分别有111个，72个。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-28</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>33页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>创新药/改良型新药</span> <span>特殊审批</span> <span>行业政策法规</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-3.png" alt="2025年2月仿制药月报"> <div class="report-name item-3">2025年2月仿制药月报</div> <div class="tag color-3">医药观察月报</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/68526.html">2025年2月仿制药月报</a></div> <div class="desc">根据摩熵数据统计，2025年2月共有27个品种（按受理号计42项）一致性评价申请获CDE承办，申请品种主要为系统用抗感染药物，申请剂型主要为注射剂。脂肪乳注射液（C14-24）为申请企业数最多的品种，有3家；江苏神龙药业有限公司、石药集团欧意药业有限公司、辰欣药业股份有限公司是申请品种最多的企业，均有2个品种。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-28</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>15页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>仿制药</span> <span>一致性评价</span> <span>仿制药政策</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-3.png" alt="2024医药健康投融资&交易年报"> <div class="report-name item-3">2024医药健康投融资&交易年报</div> <div class="tag color-3">医药观察月报</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/32564.html">2024医药健康投融资&交易年报</a></div> <div class="desc">全球医药健康交易市场2024年概况：合作协议数量最多，发生2655起。合作协议为2024年统计期间最重要的交易主题，表明医药行业的合作非常频繁且紧密，也凸显共同研发、生产及商业拓展的主流趋势。中国医药健康交易市场2024年概况：据摩熵投融资数据统计，2024年中国医药健康行业共发生交易373起，同比减少14.25%，其中，跨国交易215起，占比57.64%。跨国交易数量环比同比减少50.57%。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-21</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>21页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>医药健康</span> <span>医药投融资</span> <span>医药交易</span> </div> </div> </div> </li> </ul> <ul class="report-content content-5"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-2.png" alt="盐酸溴己新片适用人群、市场潜力及销售预测分析"> <div class="report-name item-2">盐酸溴己新片适用人群、市场潜力及销售预测分析</div> <div class="tag color-2">定制化报告</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/65536.html">盐酸溴己新片适用人群、市场潜力及销售预测分析</a></div> <div class="desc">本报告将对盐酸溴己新片患者人群、竞争格局、销售额潜力进行全面深入的研究和分析，包括药物作用机理与相关临床试验结果梳理、适应症患者人群分析、药物竞争格局分析、药物潜力分析与销售额预测等方面。旨在为医药行业相关从业人员提供盐酸溴己新片市场分析和销售额预测的参考。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-21</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>40页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>盐酸溴己新片</span> <span>患者池</span> <span>销售额预测</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-1.png" alt="二硫化硒洗剂适用人群、市场潜力及销售预测分析"> <div class="report-name item-1">二硫化硒洗剂适用人群、市场潜力及销售预测分析</div> <div class="tag color-1">定制化报告</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/65792.html">二硫化硒洗剂适用人群、市场潜力及销售预测分析</a></div> <div class="desc">本报告将对二硫化硒洗剂患者人群、竞争格局、销售额潜力进行全面深入的研究和分析，包括药物作用机理与相关临床试验结果梳理、适应症患者人群分析、药物竞争格局分析、药物潜力分析与销售额预测等方面。旨在为医药行业相关从业人员提供二硫化硒洗剂市场分析和销售额预测的参考。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-21</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>74页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>患者池</span> <span>销售额预测</span> <span>二硫化硒洗剂</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="/assets/images/common/img-report-3.png" alt="肠内营养混悬液(TPF-FOS)适用人群、市场潜力及销售预测分析"> <div class="report-name item-3">肠内营养混悬液(TPF-FOS)适用人群、市场潜力及销售预测分析</div> <div class="tag color-2">定制化报告</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" target="_blank" href="https://consult.pharnexcloud.com/report/detail/66048.html">肠内营养混悬液(TPF-FOS)适用人群、市场潜力及销售预测分析</a></div> <div class="desc">本报告将对肠内营养混悬液(TPF-FOS)患者人群、竞争格局、销售额潜力进行全面深入的研究和分析，包括药物作用机理与相关临床试验结果梳理、适应症患者人群分析、药物竞争格局分析、药物潜力分析与销售额预测等方面。旨在为医药行业相关从业人员提供肠内营养混悬液(TPF-FOS)市场分析和销售额预测的参考。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵咨询</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-21</div> <div class="info-item page"><i class="icon iconfont icon-menhu-yema"></i>44页</div> <div class="info-item"><i class="icon iconfont icon-menhu-biaoqian"></i> <span>患者池</span> <span>销售额预测</span> <span>肠内营养混悬液(TPF-FOS)</span> </div> </div> </div> </li> </ul> </div> <div class="right"> <div class="model"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/cards/category-card.css?v=20250403"> <div class="component-card category-card" style="--color: #FF8A1E;"> <div class="title"> <h3 class="title-name">报告专题</h3> <div class="more"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-0">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <ul class="list"> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-65">消化系统与代谢药物</a></li> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-67">皮肤病药物</a></li> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-26">罕见病</a></li> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-28">其他</a></li> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-55">补气补血药物</a></li> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-56">全身用激素类制剂(不含性激素和胰岛素)</a></li> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-58">呼吸系统药物</a></li> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-59">心血管系统药物</a></li> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-60">感觉系统药物</a></li> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-61">抗寄生虫药物、杀虫药物和驱虫药物</a></li> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-62">抗肿瘤药</a></li> <li class="item"><a target="_blank" href="https://consult.pharnexcloud.com/report/0-0-0-71">血液和造血系统药物</a></li> </ul> </div> </div> </div> <div class="model"> <link rel="stylesheet" href="https://www.pharnexcloud.com/assets/css/cards/live-card.css?v=20250403"> <div class="component-card live-card" style="--color: #07AEA0;"> <div class="title"> <h3 class="title-name">摩熵说直播</h3> <div class="more"><a href="https://consult.pharnexcloud.com/live" target="_blank">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <ul class="list"> <li class="item" onclick="targetBlank(this)"> <div class="tag">往期回放 </div> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/live_images/202503/28/b0388c114b01b13675e0e6ff4777ded4.jpg" alt="医药行业中的AI应用与未来趋势"> <div class="cover"> <div class="play-btn"></div> </div> <p class="name"><a onclick="return false" href="https://consult.pharnexcloud.com/live/detail/80.html" target="_blank" title="医药行业中的AI应用与未来趋势">医药行业中的AI应用与未来趋势</a></p> </li> <li class="item"><a href="https://consult.pharnexcloud.com/live/detail/79.html" target="_blank" title="药品专利期限调整制度引入对药品企业项目管理和许可的影响">药品专利期限调整制度引入对药品企业项目管理和许可的影响</a></li> <li class="item"><a href="https://consult.pharnexcloud.com/live/detail/78.html" target="_blank" title="DTP模式当下的合规管理要求">DTP模式当下的合规管理要求</a></li> <li class="item"><a href="https://consult.pharnexcloud.com/live/detail/77.html" target="_blank" title="2024全球新药数据盘点：FDA与NMPA的“新药风向标”">2024全球新药数据盘点：FDA与NMPA的“新药风向标”</a></li> </ul> </div> </div> </div> </div> </div> <div class="container container4 m"> <div class="title"> <h2 class="title-name">推荐专题</h2> <div class="more"><a target="_blank" href="https://www.pharnexcloud.com/zhuanti">更多专题<i class="icon iconfont icon-gengduojiantou"></i></a></div> </div> <div class="project-content"> <div class="project-item" onclick="targetBlank(this)"> <img class="img" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202501/16/0241b0311482dea17beca9cfe912cc1f.png" alt="医药市场研究分析"> <div class="project-name"> <a href="https://www.pharnexcloud.com/zhuanti/6" target="_blank" onclick="return false" class="text">医药市场研究分析</a> </div> </div> <div class="project-item" onclick="targetBlank(this)"> <img class="img" src="https://yaorongyun-test-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202411/12/bb760b2836cf8af42f7133e41db8f8a5.png" alt="全球创新药研发概览"> <div class="project-name"> <a href="https://www.pharnexcloud.com/zhuanti/1" target="_blank" onclick="return false" class="text">全球创新药研发概览</a> </div> </div> <div class="project-item" onclick="targetBlank(this)"> <img class="img" src="https://yaorongyun-test-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202411/12/5b6140e2197e4d6cadcba1412615e70f.png" alt="全球医药大健康行业投融资数据"> <div class="project-name"> <a href="https://www.pharnexcloud.com/zhuanti/2" target="_blank" onclick="return false" class="text">全球医药大健康行业投融资数据</a> </div> </div> <div class="project-item" onclick="targetBlank(this)"> <img class="img" src="https://yaorongyun-test-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202411/12/0734f3d19fb56843884850e52255ab28.png" alt="国内医药大健康行业政策法规汇总"> <div class="project-name"> <a href="https://www.pharnexcloud.com/zhuanti/3" target="_blank" onclick="return false" class="text">国内医药大健康行业政策法规汇总</a> </div> </div> <div class="project-item" onclick="targetBlank(this)"> <img class="img" src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/database_images/202502/07/d0ed1d0d9bb82b328ca596040a601b38.png" alt="国内仿制药/生物类似物申报/审批数据分析"> <div class="project-name"> <a href="https://www.pharnexcloud.com/zhuanti/4" target="_blank" onclick="return false" class="text">国内仿制药/生物类似物申报/审批数据分析</a> </div> </div> </div> </div> <div class="images m"> <a onclick="advertAddClick(2)" target="_blank" rel="nofollow" href="https://vip.pharnexcloud.com/?auto=1&from=menhu-zhongjianguanggao2" ><img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/ad_images/202503/06/75fd2d2f8f5ef19b2d7915e1bbef93b2.jpg" alt="摩熵医药企业版"></a> </div> <div class="container container3 m"> <div class="left"> <div class="left-title"> <h2 class="title-name">摩熵<span>原创</span></h2> <ul class="tabs"> <li data-category="0" data-id="content-1" class="tab-item active">最新</li> <li data-category="4" data-id="content-sdfx" data-abbreviation="sd" class="tab-item">深度分析</li> <li data-category="15" data-id="content-gpjx" data-abbreviation="gpjx" class="tab-item">过评精选</li> <li data-category="5" data-id="content-zcfg" data-abbreviation="zc" class="tab-item">政策法规</li> <li data-category="14" data-id="content-sdsl" data-abbreviation="sdsl" class="tab-item">赛道梳理</li> <li data-category="1" data-id="content-trz" data-abbreviation="trz" class="tab-item">投融资</li> <li data-category="16" data-id="content-zcsp" data-abbreviation="zcsp" class="tab-item">注册审批</li> </ul> <div class="more"><a target="_blank" href="https://www.pharnexcloud.com/zixun/yuanchuang">更多</a><i class="icon iconfont icon-gengduojiantou"></i></div> </div> <ul class="report-content content-1 active-content"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/08/1ccf49632c2ddb9cffd7a47c8e36d4fb.png" alt="百济神州欧司珀利单抗折戟肺癌：TIGIT靶点研发遇冷，免疫治疗挑战重重"> <div class="tag color-1">时讯</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sx_42643" target="_blank">百济神州欧司珀利单抗折戟肺癌：TIGIT靶点研发遇冷，免疫治疗挑战重重</a></div> <div class="desc">4月3日，百济神州宣布终止抗TIGIT抗体欧司珀利单抗治疗肺癌的临床开发项目，此前已投入20.90亿元。TIGIT靶点曾被寄予厚望，但罗氏、BMS、默沙东等药企接连失利，百济神州也屡遭挫折，不过该靶点在肝癌等领域仍有研究，其困境反映了肿瘤免疫治疗的系统性挑战。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item"> <span>百济神州</span> <span>欧司珀利单抗</span> <span>TIGIT靶点</span> <span>新药研发</span> <span>免疫治疗</span> <span>肺癌</span> <span>临床试验</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/08/844bbe8de485a77beb0649754a7e293b.png" alt="和誉医药与默克深度合作：8500万美元行权费落定，匹米替尼领航CSF-1R抑制剂赛道新征程"> <div class="tag color-3">时讯</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sx_42642" target="_blank">和誉医药与默克深度合作：8500万美元行权费落定，匹米替尼领航CSF-1R抑制剂赛道新征程</a></div> <div class="desc">4月1日，和誉医药宣布默克行使匹米替尼全球商业化选择权，行权费8500万美元。匹米替尼是和誉自主研发的CSF-1R抑制剂，在TGCT临床试验中表现优异，获多国监管机构突破性疗法认定，公司专注肿瘤靶向和免疫药物研发。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item"> <span>和誉医药</span> <span>默克</span> <span>匹米替尼</span> <span>CSF-1R抑制剂</span> <span>企业合作</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/08/ed19547096fe0b66b2b128014788db1c.png" alt="2024版医保目录新增91款药品，化药占比超六成"> <div class="tag color-1">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42640" target="_blank">2024版医保目录新增91款药品，化药占比超六成</a></div> <div class="desc">本文基于摩熵咨询最新发布的《2024年医保谈判及市场分析报告》部分内容，探讨医保谈判在价格调控和患者可负担性方面积极作用。同时，医保谈判将众多优质创新药品纳入医保目录，极大激发了医药企业的创新积极性，推动整个医药产业向创新驱动型转变，不断推出更多满足临床需求的创新药，为患者带来更多治疗选择和希望。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item"> <span>2024版医保目录</span> <span>医保目录</span> <span>化药</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/08/5021d3cca71577d5c73bd3ab4b75b82b.png" alt="2024年医保药品市场规模超 1.2 万亿，肿瘤药成销售焦点"> <div class="tag color-2">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42639" target="_blank">2024年医保药品市场规模超 1.2 万亿，肿瘤药成销售焦点</a></div> <div class="desc">本文基于摩熵咨询最新发布的《2024年医保谈判及市场分析报告》部分内容，探讨医保谈判对医药企业、医疗市场格局以及患者用药可及性和负担的影响，揭示医保谈判在推动医药行业创新发展、促进医疗资源合理配置中的关键作用，旨在为医药企业及相关从业者提供全面且深入的参考依据。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item"> <span>医保药品市场</span> <span>医疗保险</span> <span>肿瘤药物</span> <span>药品销售</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/08/69ffc57cbd3548eac8a32689eb5ead4e.png" alt="2024年医保谈判规则大揭秘，多款药品借续约抢占市场高地"> <div class="tag color-3">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42638" target="_blank">2024年医保谈判规则大揭秘，多款药品借续约抢占市场高地</a></div> <div class="desc">本文基于摩熵咨询最新发布的《2024年医保谈判及市场分析报告》部分内容，深入剖析医保谈判政策变化，以及其在推动医药行业创新、优化医疗资源配置进程中扮演的重要角色，为医药企业及行业从业者提供全面的洞察视角。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item"> <span>医保谈判</span> <span>医保谈判规则</span> <span>医疗保险</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/08/495a880bf3c3dae4df0d3357637fd8c7.png" alt="2024年医保谈判及市场分析报告（附下载）"> <div class="tag color-3">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42641" target="_blank">2024年医保谈判及市场分析报告（附下载）</a></div> <div class="desc">本报告结合市场数据分析，探讨医保谈判对医药企业、医疗市场格局以及患者用药可及性和负担的影响，揭示医保谈判在推动医药行业创新发展、促进医疗资源合理配置中的关键作用，旨在为医药企业及相关从业者提供全面且深入的参考依据。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item"> <span>医保谈判</span> <span>医疗保险</span> <span>市场分析</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/961dea753c12c48ac5d327b34738f087.png" alt="立方制药帕利哌酮缓释片获批上市，抗精神病药销售格局与竞争解析"> <div class="tag color-3">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_42539" target="_blank">立方制药帕利哌酮缓释片获批上市，抗精神病药销售格局与竞争解析</a></div> <div class="desc">立方制药申报的4类仿制药帕利哌酮缓释片（6mg、3mg）获批生产并视同过评，适用于成人及12-17岁青少年精神分裂症治疗，立方制药为第5家获批上市企业。原研为杨森制药，近年来该药成为抑郁症一线用药，进入医保。从2024年前三季度销售额竞争格局看，首仿豪森药业占比56%，杨森制药占比40%。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>立方制药</span> <span>帕利哌酮缓释片</span> <span>药品审评审批</span> <span>抗精神病药物</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/c46dfe0a9295571577d766671fae0b30.png" alt="罗氏奥瑞利珠单抗高剂量III期研究折戟，股价受挫，600mg剂量仍为RMS治疗优选"> <div class="tag color-2">时讯</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sx_42538" target="_blank">罗氏奥瑞利珠单抗高剂量III期研究折戟，股价受挫，600mg剂量仍为RMS治疗优选</a></div> <div class="desc">4月2日，罗氏宣布高剂量奥瑞利珠单抗治疗复发性多发性硬化症的III期MUSETTE研究未达主要终点，股价跌4.16%。奥瑞利珠单抗2017年美国获批，2024年销售额达74.61亿美元。此次研究证实600mg为减缓残疾进展的最佳剂量。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>罗氏</span> <span>奥瑞利珠单抗</span> <span>临床试验</span> <span>股价</span> <span>RMS治疗</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/1c82a7c2ff10f4261e64e957c91f6957.png" alt="【数据库更新】6大数据库功能升级，新增加拿大临床试验数据，微信订阅+PDF下载..."> <div class="tag color-1">时讯</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sx_42537" target="_blank">【数据库更新】6大数据库功能升级，新增加拿大临床试验数据，微信订阅+PDF下载...</a></div> <div class="desc">摩熵医药数据库本次更新对6个数据库的功能进行了升级优化，新增下载药物报告、快速检索、创新类型筛选项等功能，还新增药品招投标、全球临床试验数据库数据，新增加拿大临床试验数据，同时升级订阅功能，上线网页端和微信小程序，方便用户随时随地掌握医药信息。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>摩熵医药数据库</span> <span>数据库更新</span> <span>数据库功能优化</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/cfa334cb6e39b17c1088a8857d10710b.png" alt="2025年靶向免疫抑制药物市场趋势：新药、新靶点、新剂型、新治疗方式"> <div class="tag color-1">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42535" target="_blank">2025年靶向免疫抑制药物市场趋势：新药、新靶点、新剂型、新治疗方式</a></div> <div class="desc">摩熵咨询发布的《自免药物（JAK抑制剂篇）市场研究专题报告》以其深入的行业洞察系统剖析了JAK抑制剂的作用机制、市场竞争格局及靶向药物未来趋势。本文将基于报告核心内容，揭示靶向免疫药物市场的四大关键趋势。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>自免药物</span> <span>JAK抑制剂</span> <span>药物市场趋势分析</span> <span>新药研发</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/40c5a0bd6786ec251d54170b45ba3f00.png" alt="2024年JAK抑制剂市场竞争格局分析：芦可替尼8.6亿领跑，仿制药挑战在即"> <div class="tag color-3">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42534" target="_blank">2024年JAK抑制剂市场竞争格局分析：芦可替尼8.6亿领跑，仿制药挑战在即</a></div> <div class="desc">摩熵咨询发布的《自免药物（JAK抑制剂篇）市场研究专题报告》系统梳理了JAK抑制剂的作用机制、上市药物及市场竞争格局，并结合医保政策、仿制药冲击、适应症拓展等维度，为中国市场的战略布局提供了关键洞察。本文基于该报告核心内容，为您深入解析JAK抑制剂市场的竞争态势与未来趋势。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>自免药物</span> <span>JAK抑制剂</span> <span>药物市场竞争格局</span> <span>芦可替尼</span> <span>仿制药</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/2df1cf08117e9538885aa9837ff8eef2.png" alt="2024年自免药物JAK抑制剂：上市药物、指南推荐、临床应用...."> <div class="tag color-3">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42533" target="_blank">2024年自免药物JAK抑制剂：上市药物、指南推荐、临床应用....</a></div> <div class="desc">本文选自摩熵咨询《自免药物（JAK抑制剂篇）市场研究专题报告》的部分核心内容，深入解析JAK抑制剂的作用机制及临床应用进展。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>自免药物</span> <span>JAK抑制剂</span> <span>上市药物</span> <span>药物指南推荐</span> <span>临床应用</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/ec066e85ab1b564a51dad871a4619809.png" alt="自免药物（JAK抑制剂篇）市场研究专题报告（附下载）"> <div class="tag color-3">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42536" target="_blank">自免药物（JAK抑制剂篇）市场研究专题报告（附下载）</a></div> <div class="desc">本报告介绍了JAK抑制剂作用机制及上市药物，并分析了JAK抑制剂的市场竞争格局，为理解中国JAK抑制剂市场的现状和未来趋势提供了深入的视角。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>自免药物</span> <span>JAK抑制剂</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/03/b4be236c478124d1f69b0c5a6ad12bcc.png" alt="2025年第13周03.24-03.30全球创新药研发概览"> <div class="tag color-3">医药洞见</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/bg_42214" target="_blank">2025年第13周03.24-03.30全球创新药研发概览</a></div> <div class="desc">根据摩熵医药数据库统计，2025.03.24-2025.03.30期间全球TOP10创新药研发取得重要进展，包括神济昌华SNUG01、云顶新耀EVM14注射液等多款药物在美国、中国等地获批临床或上市，用于治疗肌萎缩侧索硬化、非小细胞肺癌等多种疾病。同时，多家公司公布积极临床数据，为新药研发提供有力支持。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-03</div> <div class="info-item"> <span>全球创新药</span> <span>药物研发</span> <span>周报</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/03/8b8a8a322613572dde98710e61ffbc3a.png" alt="2025年第13周03.24-03.30国内医药大健康行业政策法规汇总"> <div class="tag color-1">医药洞见</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/bg_42213" target="_blank">2025年第13周03.24-03.30国内医药大健康行业政策法规汇总</a></div> <div class="desc">根据摩熵医药数据库统计，2025.03.24-2025.03.30期间国内医药大健康行业政策包括：国家药监局发布2025年版《中华人民共和国药典》实施公告，国家卫健委发布儿童CT检查辐射剂量标准，以及规范公立医疗机构预交金管理的通知，旨在保障药品质量、降低儿童辐射风险、整治预交金管理乱象。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-03</div> <div class="info-item"> <span>医药大健康</span> <span>政策法规</span> <span>周报</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/03/7a3e5a93a2f2ab33776748ee08613afa.png" alt="2025年第13周03.24-03.30国内仿制药/生物类似物申报/审批数据分析"> <div class="tag color-1">医药洞见</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/bg_42212" target="_blank">2025年第13周03.24-03.30国内仿制药/生物类似物申报/审批数据分析</a></div> <div class="desc">根据摩熵医药数据库统计，2025.03.24-2025.03.30期间共有95项仿制药申报上市/申报临床获CDE承办，其中新注册分类上市申请受理号79项，新注册分类临床申请受理号9项，一致性评价申请7项。本周12个品种通过一致性评价，无视同通过一致性评价品种，无生物类似物注册申报动态。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-03</div> <div class="info-item"> <span>仿制药</span> <span>生物类似物</span> <span>药物申报审批</span> <span>数据分析</span> <span>周报</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/03/7201fe0146e143a6be4618f0b0bead33.png" alt="2025年第13周03.24-03.30国内创新药/改良型新药申请临床/获批临床/申请上市/获批上市数据分析"> <div class="tag color-2">医药洞见</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/bg_42211" target="_blank">2025年第13周03.24-03.30国内创新药/改良型新药申请临床/获批临床/申请上市/获批上市数据分析</a></div> <div class="desc">根据摩熵医药数据库统计，2025.03.24-2025.03.30期间共有69个创新药/改良型新药临床申请/上市申请获国家药品监督管理局药品审评中心（CDE）承办。其中国产药品受理号41个，进口药品受理号28个，共计64款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药33款，生物药30款，中药1款。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-03</div> <div class="info-item"> <span>创新药</span> <span>改良型新药</span> <span>药物审评审批</span> <span>数据分析</span> <span>周报</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/f715468a791b78e0b0f9354a5cbfce03.png" alt="抗病毒药物盐酸伐昔洛韦片热销，宜昌人福药业等六家企业过评"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_42195" target="_blank">抗病毒药物盐酸伐昔洛韦片热销，宜昌人福药业等六家企业过评</a></div> <div class="desc">4月1日，宜昌人福药业提交的原6类仿制药盐酸伐昔洛韦片获批并通过一致性评价，成为国产第6家过评企业。盐酸伐昔洛韦片具有较好市场潜力，人福药业2025年至今已有7款品种过评。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-03</div> <div class="info-item"> <span>抗病毒药物</span> <span>盐酸伐昔洛韦片</span> <span>宜昌人福药业</span> <span>仿制药</span> <span>药品审评审批</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/90163c0bdb2e398ff25f9d90472cc1fd.png" alt="摩熵数科助力成都市新都区卫健系统医院数字化培训，共探医疗大数据与AI未来"> <div class="tag color-2">时讯</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sx_42194" target="_blank">摩熵数科助力成都市新都区卫健系统医院数字化培训，共探医疗大数据与AI未来</a></div> <div class="desc">3月20日，摩熵数科创始人王中健博士受邀出席成都市新都区人民医院主办的“香城杏林讲坛”，围绕“大模型时代医疗大数据的临床应用与产业转化”展开专题授课，助力医疗行业数字化转型，提供极具前瞻性与实操性的前沿思路。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-03</div> <div class="info-item"> <span>摩熵数科</span> <span>医院数字化</span> <span>大数据</span> <span>AI</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/ad7db8747dadbe11f0e9abf97d9e1540.png" alt="扬子江药业获批泊马度胺胶囊，国内第三家仿制药企入局"> <div class="tag color-1">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_42082" target="_blank">扬子江药业获批泊马度胺胶囊，国内第三家仿制药企入局</a></div> <div class="desc">3月31日，扬子江药业提交的泊马度胺胶囊仿制药上市申请获NMPA批准，成为国内第三家获批企业。泊马度胺是一种治疗血液肿瘤的免疫调节剂，全球销售额快速增长。原研产品未在国内上市，但国内已有三家企业仿制药视同过评。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-02</div> <div class="info-item"> <span>扬子江药业</span> <span>泊马度胺胶囊</span> <span>仿制药</span> <span>药品审评审批</span> </div> </div> </div> </li> </ul> <ul class="report-content content-sdfx"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/08/ed19547096fe0b66b2b128014788db1c.png" alt="2024版医保目录新增91款药品，化药占比超六成"> <div class="tag color-2">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42640" target="_blank">2024版医保目录新增91款药品，化药占比超六成</a></div> <div class="desc">本文基于摩熵咨询最新发布的《2024年医保谈判及市场分析报告》部分内容，探讨医保谈判在价格调控和患者可负担性方面积极作用。同时，医保谈判将众多优质创新药品纳入医保目录，极大激发了医药企业的创新积极性，推动整个医药产业向创新驱动型转变，不断推出更多满足临床需求的创新药，为患者带来更多治疗选择和希望。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item"> <span>2024版医保目录</span> <span>医保目录</span> <span>化药</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/08/5021d3cca71577d5c73bd3ab4b75b82b.png" alt="2024年医保药品市场规模超 1.2 万亿，肿瘤药成销售焦点"> <div class="tag color-3">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42639" target="_blank">2024年医保药品市场规模超 1.2 万亿，肿瘤药成销售焦点</a></div> <div class="desc">本文基于摩熵咨询最新发布的《2024年医保谈判及市场分析报告》部分内容，探讨医保谈判对医药企业、医疗市场格局以及患者用药可及性和负担的影响，揭示医保谈判在推动医药行业创新发展、促进医疗资源合理配置中的关键作用，旨在为医药企业及相关从业者提供全面且深入的参考依据。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item"> <span>医保药品市场</span> <span>医疗保险</span> <span>肿瘤药物</span> <span>药品销售</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/08/69ffc57cbd3548eac8a32689eb5ead4e.png" alt="2024年医保谈判规则大揭秘，多款药品借续约抢占市场高地"> <div class="tag color-2">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42638" target="_blank">2024年医保谈判规则大揭秘，多款药品借续约抢占市场高地</a></div> <div class="desc">本文基于摩熵咨询最新发布的《2024年医保谈判及市场分析报告》部分内容，深入剖析医保谈判政策变化，以及其在推动医药行业创新、优化医疗资源配置进程中扮演的重要角色，为医药企业及行业从业者提供全面的洞察视角。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item"> <span>医保谈判</span> <span>医保谈判规则</span> <span>医疗保险</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/08/495a880bf3c3dae4df0d3357637fd8c7.png" alt="2024年医保谈判及市场分析报告（附下载）"> <div class="tag color-3">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42641" target="_blank">2024年医保谈判及市场分析报告（附下载）</a></div> <div class="desc">本报告结合市场数据分析，探讨医保谈判对医药企业、医疗市场格局以及患者用药可及性和负担的影响，揭示医保谈判在推动医药行业创新发展、促进医疗资源合理配置中的关键作用，旨在为医药企业及相关从业者提供全面且深入的参考依据。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-08</div> <div class="info-item"> <span>医保谈判</span> <span>医疗保险</span> <span>市场分析</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/cfa334cb6e39b17c1088a8857d10710b.png" alt="2025年靶向免疫抑制药物市场趋势：新药、新靶点、新剂型、新治疗方式"> <div class="tag color-2">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42535" target="_blank">2025年靶向免疫抑制药物市场趋势：新药、新靶点、新剂型、新治疗方式</a></div> <div class="desc">摩熵咨询发布的《自免药物（JAK抑制剂篇）市场研究专题报告》以其深入的行业洞察系统剖析了JAK抑制剂的作用机制、市场竞争格局及靶向药物未来趋势。本文将基于报告核心内容，揭示靶向免疫药物市场的四大关键趋势。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>自免药物</span> <span>JAK抑制剂</span> <span>药物市场趋势分析</span> <span>新药研发</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/40c5a0bd6786ec251d54170b45ba3f00.png" alt="2024年JAK抑制剂市场竞争格局分析：芦可替尼8.6亿领跑，仿制药挑战在即"> <div class="tag color-2">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42534" target="_blank">2024年JAK抑制剂市场竞争格局分析：芦可替尼8.6亿领跑，仿制药挑战在即</a></div> <div class="desc">摩熵咨询发布的《自免药物（JAK抑制剂篇）市场研究专题报告》系统梳理了JAK抑制剂的作用机制、上市药物及市场竞争格局，并结合医保政策、仿制药冲击、适应症拓展等维度，为中国市场的战略布局提供了关键洞察。本文基于该报告核心内容，为您深入解析JAK抑制剂市场的竞争态势与未来趋势。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>自免药物</span> <span>JAK抑制剂</span> <span>药物市场竞争格局</span> <span>芦可替尼</span> <span>仿制药</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/2df1cf08117e9538885aa9837ff8eef2.png" alt="2024年自免药物JAK抑制剂：上市药物、指南推荐、临床应用...."> <div class="tag color-3">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42533" target="_blank">2024年自免药物JAK抑制剂：上市药物、指南推荐、临床应用....</a></div> <div class="desc">本文选自摩熵咨询《自免药物（JAK抑制剂篇）市场研究专题报告》的部分核心内容，深入解析JAK抑制剂的作用机制及临床应用进展。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>自免药物</span> <span>JAK抑制剂</span> <span>上市药物</span> <span>药物指南推荐</span> <span>临床应用</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/ec066e85ab1b564a51dad871a4619809.png" alt="自免药物（JAK抑制剂篇）市场研究专题报告（附下载）"> <div class="tag color-1">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42536" target="_blank">自免药物（JAK抑制剂篇）市场研究专题报告（附下载）</a></div> <div class="desc">本报告介绍了JAK抑制剂作用机制及上市药物，并分析了JAK抑制剂的市场竞争格局，为理解中国JAK抑制剂市场的现状和未来趋势提供了深入的视角。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>自免药物</span> <span>JAK抑制剂</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/6aaa8bf16043caa8075fea91ebe72ff2.png" alt="2024年七大类降糖药解析：SGLT2i为何成指南首选？"> <div class="tag color-2">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42079" target="_blank">2024年七大类降糖药解析：SGLT2i为何成指南首选？</a></div> <div class="desc">本文基于摩熵咨询《口服降糖药市场研究专题报告》，深入介绍我国糖尿病药物市场明星品种，以及第十批集采引发的仿制药竞争状况。进一步了解目前市场创新与集采博弈下，药企生存战白热化的现状。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-02</div> <div class="info-item"> <span>降糖药</span> <span>SGLT2i</span> <span>糖尿病药物</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/20ee2c39b46891b960e5e7d5b5339560.png" alt="2024年口服降糖药市场竞争格局分析：达格列净片销售居榜首，二甲双胍零售端销售强劲"> <div class="tag color-1">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42078" target="_blank">2024年口服降糖药市场竞争格局分析：达格列净片销售居榜首，二甲双胍零售端销售强劲</a></div> <div class="desc">本篇文章依托摩熵咨询《口服降糖药市场专题研究报告》，旨在为读者全面介绍口服降糖药物的市场格局和市场趋势，并深入剖析头部企业的带头作用，助力读者对降糖药形成更为系统和深入的理解。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-02</div> <div class="info-item"> <span>口服降糖药</span> <span>药物市场竞争格局</span> <span>达格列净片</span> <span>二甲双胍</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/dffb52abcbcaa700d501851d1cc4ef11.png" alt="2024年糖尿病用药新趋势：从促泌到排糖，作用机制揭秘！SGLT2i为首选降糖药物"> <div class="tag color-2">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42077" target="_blank">2024年糖尿病用药新趋势：从促泌到排糖，作用机制揭秘！SGLT2i为首选降糖药物</a></div> <div class="desc">本篇文章依托摩熵咨询《口服降糖药市场专题研究报告》，旨在为读者全面介绍口服降糖药物的种类及其应用领域，并深入剖析各类药物的作用机制，助力读者对降糖药形成更为系统和深入的理解。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-02</div> <div class="info-item"> <span>作用机制</span> <span>SGLT2i</span> <span>糖尿病</span> <span>市场研究专题报告</span> <span>降糖药</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/c0315bcd0041feeefa921f373b7538a8.png" alt="口服降糖药市场研究专题报告（附下载）"> <div class="tag color-1">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42080" target="_blank">口服降糖药市场研究专题报告（附下载）</a></div> <div class="desc">本报告深入分析了口服降糖药的竞争格局及市场趋势，为胰岛素药物领域的现状和未来趋势提供了深入的视角。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-02</div> <div class="info-item"> <span>口服降糖药</span> <span>糖尿病</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/2a35ef6e8a34cb57c6bd7679a0b1c199.png" alt="2024年抗高血压药物复方制剂市场竞争格局及发展趋势"> <div class="tag color-1">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42075" target="_blank">2024年抗高血压药物复方制剂市场竞争格局及发展趋势</a></div> <div class="desc">本文基于摩熵咨询《利尿剂——市场研究专题报告》部分精华内容，探讨了抗高血压药物复方制剂的优势、市场现状以及发展前景，为读者提供对于该行业的深入洞察。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-02</div> <div class="info-item"> <span>抗高血压药物复方制剂</span> <span>药物市场竞争格局</span> <span>发展趋势</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/ffa1d761a651008c3146f93ae08c3c2b.png" alt="2024年利尿剂市场分析：市场规模、竞争格局、集采情况…"> <div class="tag color-1">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42074" target="_blank">2024年利尿剂市场分析：市场规模、竞争格局、集采情况…</a></div> <div class="desc">本文基于摩熵咨询最新发布的《利尿剂——市场研究专题报告》部分精华内容，从市场规模、竞争格局到药物流向与集采情况详细分析了五种主流利尿剂药物的市场现状，包括呋塞米、布美他尼、氢氯噻嗪、吲达帕胺以及螺内酯，揭示利尿剂市场的复杂生态，为医药从业者与投资者提供决策参考。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-02</div> <div class="info-item"> <span>利尿剂</span> <span>药物市场分析</span> <span>药物市场竞争格局</span> <span>药品集采</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/f7638a7dddaa359eb7df44845c09a262.png" alt="2024年利尿剂概述：分类、作用机制、临床应用、市场概览"> <div class="tag color-2">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42073" target="_blank">2024年利尿剂概述：分类、作用机制、临床应用、市场概览</a></div> <div class="desc">本文基于摩熵咨询最新发布的《利尿剂——市场研究专题报告》系统梳理了利尿剂的分类、作用机制及临床应用场景，结合最新市场数据，揭示其在现代医疗体系中的实际价值，为临床实践与医药行业提供参考。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-02</div> <div class="info-item"> <span>利尿剂</span> <span>药物分类</span> <span>作用机制</span> <span>临床应用</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/019fedcf1dd5d77e93088af9345a453d.png" alt="利尿剂——市场研究专题报告（附下载）"> <div class="tag color-3">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_42076" target="_blank">利尿剂——市场研究专题报告（附下载）</a></div> <div class="desc">本报告将从利尿剂概述、利尿剂市场竞争格局分析、抗高血压药物复方制剂市场分析和抗高血压药物市场趋势四方面进行全面分析，为理解中国利尿剂药物市场的现状和未来趋势提供了深入的视角。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-02</div> <div class="info-item"> <span>利尿剂</span> <span>药物市场分析</span> <span>市场研究专题报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/01/8de0bdc126ca5e2073e94b6072d67779.png" alt="2024年四川省核药市场分析：重点企业、发展前景、产业政策"> <div class="tag color-2">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_41935" target="_blank">2024年四川省核药市场分析：重点企业、发展前景、产业政策</a></div> <div class="desc">本文选取摩熵咨询的《中国放射性药物产业白皮书》部分内容，首先分析了四川省的核药市场，包括其销售概况及重点企业分析。接着探讨了核药市场的发展潜力以及相关产业政策，旨在为相关企业和投资者提供有价值的参考信息，助力把握核药市场的未来机遇。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-01</div> <div class="info-item"> <span>核药市场分析</span> <span>发展前景</span> <span>产业政策</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/01/6ebe759cfd065b36826184febe85889a.png" alt="2024年放射性药物国内外研发现状深度解析"> <div class="tag color-1">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_41934" target="_blank">2024年放射性药物国内外研发现状深度解析</a></div> <div class="desc">本文基于摩熵咨询发布的《中国放射性药物产业白皮书》部分精华内容，将从全球新药研发、中国在研管线两个方面，深度剖析放射性新药的研发现状。通过详实的数据展示和深入的市场洞察，我们将为相关企业和投资者提供有价值的参考信息，助力把握放射性新药市场的未来机遇。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-01</div> <div class="info-item"> <span>放射性药物</span> <span>药物研发</span> <span>研发现状</span> <span>深度解析</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/01/47c626b023b47480fd277bee6a6eadd6.png" alt="2024年中国核药市场规模与竞争格局"> <div class="tag color-2">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_41932" target="_blank">2024年中国核药市场规模与竞争格局</a></div> <div class="desc">本文选取摩熵咨询发布的《中国放射性药物产业白皮书》部分精华内容，将从市场规模、竞争格局等多个维度，对中国核药市场进行深入剖析。通过数据的解读，我们将洞察核药市场的趋势与挑战，为相关企业和投资者提供有价值的参考信息，助力把握核药市场未来机遇。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-01</div> <div class="info-item"> <span>核药</span> <span>核药市场规模</span> <span>药物市场竞争格局</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/01/badefabf34ffe50e15a30ead9a8077f7.png" alt="2024年核药产业链分析：上游原料紧缺、中游入局者增多、下游医疗资源供给不足"> <div class="tag color-2">深度分析</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sd_41931" target="_blank">2024年核药产业链分析：上游原料紧缺、中游入局者增多、下游医疗资源供给不足</a></div> <div class="desc">随着全球市场的不断发展与创新，核药产业链正在逐步扩展，并在多领域表现出其巨大的商业潜力和前景。本文基于摩熵咨询最新发布的《中国放射性药物产业白皮书》的部分精华内容，深入分析了核药产业链的各个环节，并展望其未来发展。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-01</div> <div class="info-item"> <span>核药</span> <span>核药产业链</span> <span>医疗资源</span> <span>摩熵咨询报告</span> </div> </div> </div> </li> </ul> <ul class="report-content content-gpjx"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202410/16/ce65ec3a6210b1e7ccdb105541ae5b53.png" alt="亮丙瑞林微球市场潜力巨大，丽珠制药首仿过评抢占先机"> <div class="tag color-1">过评精选</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/gpjx_8617" target="_blank">亮丙瑞林微球市场潜力巨大，丽珠制药首仿过评抢占先机</a></div> <div class="desc">10月15日，上海丽珠制药的亮丙瑞林微球通过一致性评价，成为首个过评产品。该产品国内销售额高速增长，2023年销售额约54亿元。丽珠制药成为首家过评企业，显示注射微球市场潜力巨大。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药通社</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-10-16</div> <div class="info-item"> <span>亮丙瑞林微球</span> <span>丽珠制药</span> <span>首仿药</span> <span>一致性评价</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202409/18/8398ca451b6f20c1a479f906f4a0c336.png" alt="2024年8月：183个品种过评，8款首仿药获批！石家庄四药领跑"> <div class="tag color-1">过评精选</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/gpjx_8503" target="_blank">2024年8月：183个品种过评，8款首仿药获批！石家庄四药领跑</a></div> <div class="desc">2024年8月CDE受理442条新仿制药申报和46条一致性评价申请，浙江深海医药申报最多。同时，183个品种通过一致性评价，石家庄四药以7品种过评居首。此外，8款首仿药获批，涵盖阿伐替尼片等多个品种。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-09-18</div> <div class="info-item"> <span>2024年8月</span> <span>首仿药</span> <span>药物审评审批</span> <span>石家庄四药</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202409/10/1a42cf5d3adf7ed4777c02c901b6a7c0.png" alt="最新批件！48个品种过评，涉及齐鲁制药、石家庄四药、扬子江药业……"> <div class="tag color-1">过评精选</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/gpjx_8465" target="_blank">最新批件！48个品种过评，涉及齐鲁制药、石家庄四药、扬子江药业……</a></div> <div class="desc">2024年9月9日，NMPA宣布48个药品品种（65品规）通过一致性评价，包括齐鲁制药等多家企业。复方聚乙二醇电解质散等3品种两企同日过评，玻璃酸钠滴眼液等两品种三企获批。注射剂占比最高，盐酸奈福泮注射液等为首家过评。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-09-10</div> <div class="info-item"> <span>药物审评审批</span> <span>齐鲁制药</span> <span>石家庄四药</span> <span>扬子江药业</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202408/29/d4542744d8acf60930c3bdde716e7801.png" alt="最新批件！44个品种过评，涉及福元医药、人福药业、浙江亚太药业……"> <div class="tag color-2">过评精选</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/gpjx_8399" target="_blank">最新批件！44个品种过评，涉及福元医药、人福药业、浙江亚太药业……</a></div> <div class="desc">2024年8月27日，NMPA批准44种药品（65品规）通过一致性评价，涵盖福元医药等多家药企。其中，4品种由两家企业同日过评，3药企各有2品种同日过评。美阿沙坦钾片等3品种为首家过评。更多详情见药融云数据库。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-08-29</div> <div class="info-item"> <span>药物审评审批</span> <span>福元药业</span> <span>人福药业</span> <span>浙江亚太药业</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202408/07/5ce6ecb66c83bf340457da77e6851594.png" alt="87个品种扎堆过评，涉及江苏万高药业、石家庄四药、扬子江药业……"> <div class="tag color-3">过评精选</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/gpjx_8261" target="_blank">87个品种扎堆过评，涉及江苏万高药业、石家庄四药、扬子江药业……</a></div> <div class="desc">2024年8月5日，NMPA宣布87种药品（126品规）通过一致性评价，含江苏万高药业等多家企业。其中7品种各有两家企业同日获批，5品种迎首家过评，包括阿法骨化醇滴剂等。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-08-07</div> <div class="info-item"> <span>药物审评审批</span> <span>江苏万高药业</span> <span>石家庄四药</span> <span>扬子江药业</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202407/03/d03a3064e2daaf78848c5b65b0f57d4a.png" alt="2024年6月共有249个品种过评，18款首仿获批！涉及倍特药业、齐鲁制药……"> <div class="tag color-3">过评精选</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/gpjx_8069" target="_blank">2024年6月共有249个品种过评，18款首仿获批！涉及倍特药业、齐鲁制药……</a></div> <div class="desc">据药融云数据库统计，6月CDE受理355条新注册仿制药及35条一致性评价申请，浙江赛默制药申报17个品种居首，南京海纳制药次之。共249个品种通过一致性评价，倍特药业以7品种领跑。维生素B6注射液申报企业最多，帕拉米韦注射液过评企业最多。本月还迎来了18款国内首仿药。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-07-03</div> <div class="info-item"> <span>药物审评审批</span> <span>倍特药业</span> <span>齐鲁制药</span> <span>药物研发</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202406/26/8768fb158b43ddab61f264ba76a2ca64.png" alt="2024年6月25日最新批件！59个品种过评，涉及齐鲁制药、福元药业......."> <div class="tag color-2">过评精选</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/gpjx_8034" target="_blank">2024年6月25日最新批件！59个品种过评，涉及齐鲁制药、福元药业.......</a></div> <div class="desc">2024年6月25日，NMPA公布59个药品品种（91品规）通过一致性评价，涉及齐鲁制药、福元药业等。其中，齐鲁制药获二甲双胍恩格列净片（Ⅵ）国内首仿，另有8个品种为首家过评。多家药企在多个品种上获过评，展示了行业内的竞争与合作。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-06-26</div> <div class="info-item"> <span>药物审评审批</span> <span>济川药业</span> <span>齐鲁制药</span> <span>福元药业</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202406/13/233791bb27ec62df7ef30d91c574db35.png" alt="2024年6月最新批件！67个品种过评，涉及正大天晴、科伦制药、倍特药业……"> <div class="tag color-1">过评精选</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/gpjx_7968" target="_blank">2024年6月最新批件！67个品种过评，涉及正大天晴、科伦制药、倍特药业……</a></div> <div class="desc">NMPA发布药品批准信息，67个品种（97品规）通过一致性评价，涉及多家药企。其中4个品种有2家药企过评，8个品种实现首家过评。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-06-13</div> <div class="info-item"> <span>药物审评审批</span> <span>正大天晴</span> <span>科伦制药</span> <span>倍特药业</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202406/05/00c6a3070ccae0d8040f8213c0bd8297.png" alt="172家药企167个品种过评，石家庄四药领跑过评榜！"> <div class="tag color-3">过评精选</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/gpjx_7940" target="_blank">172家药企167个品种过评，石家庄四药领跑过评榜！</a></div> <div class="desc">5月CDE受理335条新注册仿制药和50条一致性评价申请，涉及超280家药企。石家庄四药等172家药企的167个品种通过一致性评价。浙江赛默和九典制药在申报上领先，石家庄四药领跑过评榜，他达拉非片等品种过评企业最多。本月16个品种迎来首家过评。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-06-05</div> <div class="info-item"> <span>药企</span> <span>药物审评审批</span> <span>石家庄四药</span> </div> </div> </div> </li> </ul> <ul class="report-content content-zcfg"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/20/80d8092e27d7edb66eb4b88dc03e8882.png" alt="国家药品集采政策再优化：15品种信息变更助力制药企业提升效率"> <div class="tag color-3">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_37888" target="_blank">国家药品集采政策再优化：15品种信息变更助力制药企业提升效率</a></div> <div class="desc">2月18日，国家组织药品联合采购办公室发布通知，允许5批国采的15个中选药品在满足条件下变更信息，包括变更上市许可持有人、企业名称、委托生产企业及新增规格包装等，并仍视为中选资格。变更措施为制药企业提供更多调整空间，整体趋势向好。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药通社</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-20</div> <div class="info-item"> <span>国家药品集采</span> <span>政策</span> <span>药企</span> <span>药品信息变更</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202501/08/447ec386bd46b5645435041843418fc8.png" alt="2025年全国医用耗材集采新规正式启动，海南率先落地！"> <div class="tag color-3">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_35439" target="_blank">2025年全国医用耗材集采新规正式启动，海南率先落地！</a></div> <div class="desc">海南省医保局与卫健委近日发布《关于落实医药集中带量采购和执行工作的通知》，标志着2025年全国耗材集采新规正式落地。新规禁止二次议价，要求中选耗材及时进院，推进医保基金与医药企业直接结算，并强化信息化监测，预示着全国耗材集采进入精细化管理新纪元。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-01-08</div> <div class="info-item"> <span>医用耗材</span> <span>医用耗材集采</span> <span>集采新规</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202412/17/b220cddbe93837fc4ff82a57425b3633.png" alt="医保改革再深化！2025年全国医保工作会议部署八大重点任务"> <div class="tag color-3">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_33277" target="_blank">医保改革再深化！2025年全国医保工作会议部署八大重点任务</a></div> <div class="desc">全国医疗保障工作会议明确2025年八大重点工作，包括加强医保基金运行管理、健全多层次医疗保障体系、顺应群众新期待、优化医保支付机制、强化医保战略购买、深化医药价格改革治理、加强医保基金监管、优化医保管理服务。2024年医保改革发展取得新进展。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-12-17</div> <div class="info-item"> <span>医保</span> <span>医疗保障工作</span> <span>医保改革</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202410/15/4e301f8737146f9d7bb4816d7b097f83.png" alt="国家药监局发布2024年药品再注册新规定，2025年1月1日起施行"> <div class="tag color-3">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_8609" target="_blank">国家药监局发布2024年药品再注册新规定，2025年1月1日起施行</a></div> <div class="desc">国家药监局发布境内生产药品再注册申报程序和资料要求（2024年第38号），2025年1月1日起实施，包括申请、受理、审查审批、送达、终止等环节，并明确了申报资料的具体要求。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>Pharma CMC</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-10-15</div> <div class="info-item"> <span>药品再注册</span> <span>国家药监局</span> <span>新规定</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202408/21/9219f01de1e52f1b3ac941b6c536560c.png" alt="药品反垄断指南出炉：全领域覆盖，力促公平竞争新生态"> <div class="tag color-3">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_8341" target="_blank">药品反垄断指南出炉：全领域覆盖，力促公平竞争新生态</a></div> <div class="desc">2024年8月9日，市场监管总局发布药品领域反垄断指南征求意见稿，共7章55条，覆盖全药品领域。指南细化垄断行为表现、执法原则和认定标准，包括垄断协议、滥用市场支配地位、经营者集中审查等，并明确法律责任。旨在规范药品市场，促进公平竞争，保护消费者权益。意见反馈至8月23日。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-08-21</div> <div class="info-item"> <span>药品</span> <span>反垄断</span> <span>意见稿</span> <span>药企</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202406/24/0b0b7ccd3832da235f0cb04f9f384307.png" alt="下月起执行！九大类耗材品种开始降价，平均降价83.46%……"> <div class="tag color-1">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_8020" target="_blank">下月起执行！九大类耗材品种开始降价，平均降价83.46%……</a></div> <div class="desc">湖南省医保局发布通知，自2024年7月1日起，全省将正式执行九类医用耗材的降价结果，包括人工晶体、运动医学等，旨在降低医疗成本。这些耗材通过集采平均降价83.46%，预计为患者带来显著利好，是医疗改革的重要进展。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>数屿医械</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-06-24</div> <div class="info-item"> <span>耗材集采</span> <span>医用耗材</span> <span>耗材降价</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202406/13/633ab77dbb2ef17de81f84c5cdfb51b8.png" alt="国家新规出台，全面彻查公立医院欠款问题！"> <div class="tag color-2">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_7970" target="_blank">国家新规出台，全面彻查公立医院欠款问题！</a></div> <div class="desc">2020年9月《保障中小企业款项支付条例》实施后，针对应收账款问题，工信部发布了修订草案并公开征求意见。修订草案加强了联合惩戒机制，要求机关、事业单位和大型企业定期报告拖欠情况，并建立了投诉平台。国务院也发布通知强调建立防范拖欠的长效机制，并缩短医疗机构回款时间至30天，以改善中小企业收款环境，促进其健康发展。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>数屿医械</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-06-13</div> <div class="info-item"> <span>政策法规</span> <span>公立医院</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202405/30/bdb6ee74fb8c846e262388bb374c995a.png" alt="国家医保局最新指令，全国严查大型医疗设备！"> <div class="tag color-1">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_7904" target="_blank">国家医保局最新指令，全国严查大型医疗设备！</a></div> <div class="desc">国家医保局发布通知，要求严查大型医疗设备检查价格，降低患者负担。各地已展开调查并降低部分检查费用，如三甲医院CT检查费降至102.6元，预计今年将迎来更多大型设备降价潮。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>数屿医械</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-05-30</div> <div class="info-item"> <span>医疗设备</span> <span>国家医保局</span> <span>政策</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202405/27/33b75c45c941ba30ee1c1ad88a3351d7.png" alt="新政策！北京发文支持CGT药物等快速形成产业增量"> <div class="tag color-1">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_7885" target="_blank">新政策！北京发文支持CGT药物等快速形成产业增量</a></div> <div class="desc">北京市发布《医药健康协同创新行动计划（2024-2026年）》，旨在加快医药健康产业发展，部署前沿技术“核爆点”专项，加强关键核心技术研究，推动临床与市场导向的创新转化，目标到2026年产业总规模达1.25万亿元，实现全球引领的科学发现和技术突破。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-05-27</div> <div class="info-item"> <span>政策</span> <span>CGT药物</span> <span>细胞疗法</span> <span>基因药物</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202402/28/cc7bac4b75bd96c1b4e163d1d1a5eb3f.png" alt="注射剂用覆膜胶塞的缺陷与对策"> <div class="tag color-2">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_7567" target="_blank">注射剂用覆膜胶塞的缺陷与对策</a></div> <div class="desc">随着国家相关政策施行，注射剂用覆膜胶塞得到了较快的发展，尤其是比较敏感的药物，更是对覆膜塞推崇备至...</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药事纵横</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-02-28</div> <div class="info-item"> <span>注射剂</span> <span>覆膜塞</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202312/26/0989a56b11dae36ba24768fb5a09573e.png" alt="重磅！第三批鼓励仿制药品目录出炉！39品种纳入，帕替司兰、伏环孢素等"> <div class="tag color-1">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_7395" target="_blank">重磅！第三批鼓励仿制药品目录出炉！39品种纳入，帕替司兰、伏环孢素等</a></div> <div class="desc">12月25日，国家卫生健康委联合工业和信息化部、国家知识产权局、国家医保局、国家疾控局、国家药监局等部门组织专家对国内专利即将到期及临床供应短缺（竞争不充分）的药品进行遴选论证，制定了《第三批鼓励仿制药品目录》。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药通社</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2023-12-26</div> <div class="info-item"> <span>仿制药研发</span> <span>目录</span> <span>国家医保局</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202312/13/09e4b656bb02f845a98570192f0cffea.png" alt="福建第四批化药集采拟中选结果，间苯三酚降价92%！30+药企扎堆申报"> <div class="tag color-3">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_7345" target="_blank">福建第四批化药集采拟中选结果，间苯三酚降价92%！30+药企扎堆申报</a></div> <div class="desc">近日，福建公布省第四批集采化药拟中选结果，结果不出意外，降价惨烈，个别品种A/B组价差之大....</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2023-12-13</div> <div class="info-item"> <span>福建集采</span> <span>急性胃肠炎</span> <span>胆囊炎</span> <span>腹痛</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202306/25/b632c82078dafc99eac13e0889188a0d.png" alt="国家药监局发文，GLP认证新《办法》7月1日执行！"> <div class="tag color-3">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_6660" target="_blank">国家药监局发文，GLP认证新《办法》7月1日执行！</a></div> <div class="desc">6月21日，国家药监局发布公告，《药物非临床研究质量管理规范认证管理办法》将于7月1日起施行。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药通社</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2023-06-25</div> <div class="info-item"> <span>药监局</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202306/20/7931b14d130566829a35eef8352911f0.png" alt="注射剂注意！《中国药典》通则（0102）注射剂修订！"> <div class="tag color-2">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_6640" target="_blank">注射剂注意！《中国药典》通则（0102）注射剂修订！</a></div> <div class="desc">6月15日，国家药典委发布关于征求《中国药典》通则（0102）注射剂修订草案意见的通知，公开征求意见自发布之日起1个月。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2023-06-20</div> <div class="info-item"> <span>注射剂</span> <span>中国药典</span> <span>药典委</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202306/15/ba65ad877e335ac381e3c6b19fc50516.png" alt="最新！CDE更新11条一般技术性问题！涉及审评审批、MAH变更等"> <div class="tag color-1">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_6618" target="_blank">最新！CDE更新11条一般技术性问题！涉及审评审批、MAH变更等</a></div> <div class="desc">6月12日，CDE更新了11条常见一般性技术问题。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药通社</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2023-06-15</div> <div class="info-item"> <span>CDE</span> <span>审评审批</span> <span>MAH</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202306/14/8b6647ef7c09c3f97a348113ece57ded.png" alt="GLP-1必备SNAC！原辅料全产业链平台完整打造，天吉生物未来可期！"> <div class="tag color-2">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_6612" target="_blank">GLP-1必备SNAC！原辅料全产业链平台完整打造，天吉生物未来可期！</a></div> <div class="desc">近日，苏州天马医药集团天吉生物制药有限公司研制的药用辅料8-(2-羟基苯甲酰胺基)辛酸钠（SNAC）登记号，已在CDE平台上公示！依托于强大的多肽药物技术平台，天吉生物成功完成SNAC的工艺开发与质量研究。严格遵循原料药研制标准对SNAC进行研制，最大程度保障了SNAC的产品质量。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药融圈</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2023-06-14</div> <div class="info-item"> <span>GLP-1</span> <span>天吉生物</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202306/13/994c1c3e5b60c083424c02f905827035.png" alt="重磅！医保目录调整方案公开征求意见！"> <div class="tag color-3">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_6597" target="_blank">重磅！医保目录调整方案公开征求意见！</a></div> <div class="desc">6月9日，国家医保局公布了《2023年国家基本医疗保险、工伤保险和生育保险药品目录调整工作方案（征求意见稿）》以及《2023年国家基本医疗保险、工伤保险和生育保险药品目录调整申报指南（征求意见稿）》。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药通社</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2023-06-13</div> <div class="info-item"> <span>医保目录</span> <span>医保局</span> <span>征求意见</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202306/12/f7d251160669a81ef1a113dc2377ad06.png" alt="2023年中国科学院院士增选79名，药剂学方向优先！"> <div class="tag color-2">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_6590" target="_blank">2023年中国科学院院士增选79名，药剂学方向优先！</a></div> <div class="desc">近期，中国科学院与中国工程院分别发布了2023年院士增选计划，2023年中国科学院院士增选名额共79名。其中，中国工程院院士增选的领域学科方向，医药卫生学部药学组，建议名额2-3个，专业学科方向为药学，优先学科方向为药剂学！</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药通社</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2023-06-12</div> <div class="info-item"> <span>药剂学</span> <span>中国科学院</span> <span>中国工程院</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202305/30/a918d644d577e892dca619d0ab21c714.png" alt="CDE最新发布通知，公开征求GCP指导原则！"> <div class="tag color-3">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_6506" target="_blank">CDE最新发布通知，公开征求GCP指导原则！</a></div> <div class="desc">5月29日，CDE发布通知，公开征求ICH《E6（R3）：药物临床试验质量管理规范（GCP）》指导原则及附件1草案。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药通社</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2023-05-30</div> <div class="info-item"> <span>CDE</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202305/29/61a17d77674ce60732cf0345def8cf15.png" alt="鼓励研发！卫健委开出29个临床急需儿童用药，均未在国内上市！"> <div class="tag color-2">政策法规</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zc_6498" target="_blank">鼓励研发！卫健委开出29个临床急需儿童用药，均未在国内上市！</a></div> <div class="desc">5月26日，国家卫健委药物政策与基本药物制度司发布《第四批鼓励研发申报儿童药品建议清单》，清单共有29个药品在列，均为尚未在国内注册上市且临床急需儿童用药。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药通社</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2023-05-29</div> <div class="info-item"> <span>卫健委</span> <span>儿童用药</span> </div> </div> </div> </li> </ul> <ul class="report-content content-sdsl"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/28/655774b1809d21b11306c3133bbe9e44.png" alt="湖南科伦制药申报比拉斯汀上市申请获受理，高效治疗过敏性鼻炎与荨麻疹新药有望面世"> <div class="tag color-2">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_41503" target="_blank">湖南科伦制药申报比拉斯汀上市申请获受理，高效治疗过敏性鼻炎与荨麻疹新药有望面世</a></div> <div class="desc">2025年3月25日，湖南科伦制药的比拉斯汀口服溶液上市申请获受理。比拉斯汀为新一代抗组胺药，有优势于第一代抗组胺药，且为过敏性鼻炎和荨麻疹提供了新的治疗药物选择。目前众多企业申报，竞争激烈，抗组胺药物市场前景广阔。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-28</div> <div class="info-item"> <span>抗组胺药</span> <span>比拉斯汀</span> <span>药品审评审批</span> <span>过敏性鼻炎</span> <span>荨麻疹</span> <span>湖南科伦制药</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/26/0e45dcd23ff5bc105d186d7eddb2fadb.png" alt="2024中药企业年报解读：华润三九、片仔癀稳步增长，白云山、健民集团..."> <div class="tag color-1">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_41321" target="_blank">2024中药企业年报解读：华润三九、片仔癀稳步增长，白云山、健民集团...</a></div> <div class="desc">2024年中药企业年报陆续发布，华润三九、片仔癀等头部企业实现营收和净利润双增长，而白云山、健民集团等部分企业面临营收或净利润下滑。江中药业营收微降但净利润逆势增长，非处方药业务表现亮眼。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-26</div> <div class="info-item"> <span>中药企业</span> <span>2024年报</span> <span>华润三九</span> <span>片仔癀</span> <span>白云山</span> <span>健民集团</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/24/b04dbcac641da6dc565848e82e08782b.png" alt="国产JAK1抑制剂再添一员！恒瑞医药硫酸艾玛昔替尼片获批上市，治疗强直性脊柱炎"> <div class="tag color-2">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_40970" target="_blank">国产JAK1抑制剂再添一员！恒瑞医药硫酸艾玛昔替尼片获批上市，治疗强直性脊柱炎</a></div> <div class="desc">3月21日，恒瑞医药自主研发的1类创新药硫酸艾玛昔替尼片（艾速达）获批上市，用于治疗活动性强直性脊柱炎成人患者。这是我国自免领域JAK抑制剂的重要突破。同时，恒瑞医药的“双艾”疗法再次未获美国FDA批准，国际化道路遇挑战。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-24</div> <div class="info-item"> <span>JAK1抑制剂</span> <span>恒瑞医药</span> <span>硫酸艾玛昔替尼片</span> <span>获批上市</span> <span>强直性脊柱炎</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/19/ef209032e732edf2f537b6adaffed2d6.png" alt="2025抗精神病药物最新消息丨KarXT国内上市在即，Emraclidine、Iclepertin、luvadaxistat..."> <div class="tag color-1">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_40483" target="_blank">2025抗精神病药物最新消息丨KarXT国内上市在即，Emraclidine、Iclepertin、luvadaxistat...</a></div> <div class="desc">2025年抗精神病药物取得重大进展，为全球约10亿受精神健康问题困扰的人带来新希望。多种新药如KarXT、Iclepertin、MK-8189等正在研发后期阶段，针对精神分裂症等精神疾病。未来，多靶点药物、精准医疗与个性化治疗将成为发展趋势。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-19</div> <div class="info-item"> <span>抗精神病药物</span> <span>新药研发</span> <span>KarXT</span> <span>Emraclidine</span> <span>Iclepertin</span> <span>luvadaxistat</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/19/db54c9087982e64bc2795ec7e71205f0.png" alt="阿斯利康10亿美金收购EsoBiotec加速体内CAR-T疗法革新！多笔交易布局细胞治疗与肿瘤药物"> <div class="tag color-3">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_40481" target="_blank">阿斯利康10亿美金收购EsoBiotec加速体内CAR-T疗法革新！多笔交易布局细胞治疗与肿瘤药物</a></div> <div class="desc">阿斯利康近期宣布多笔交易，包括10亿美元收购EsoBiotec获取其ENaBL平台，推进体内细胞疗法；同时与Alteogen达成ALT-B4独家许可协议，探索肿瘤药物皮下制剂创新。此外，阿斯利康还豪掷12亿美元收购亘喜生物，布局细胞疗法领域。行业竞速，多家制药巨头也在积极布局体内CAR-T疗法。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-19</div> <div class="info-item"> <span>阿斯利康</span> <span>EsoBiotec</span> <span>CAR-T疗法</span> <span>企业收购</span> <span>企业布局</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/17/f69eb999d901dc849e3ecbc57a48b374.png" alt="信达生物：中国首款TED药物替妥尤单抗获批，盘点国内眼科赛道“抢滩者”"> <div class="tag color-1">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_40227" target="_blank">信达生物：中国首款TED药物替妥尤单抗获批，盘点国内眼科赛道“抢滩者”</a></div> <div class="desc">2025年3月14日，信达生物的“替妥尤单抗”获批上市，成为中国首款TED药物，为甲状腺眼病治疗带来新选择。信达生物在眼科领域布局广泛，研发多款多靶点药物。国内眼科市场竞争激烈，本土药企试图打破跨国药企垄断。TED市场潜力巨大，信达生物需采取策略稳坐龙头地位。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药事纵横</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-17</div> <div class="info-item"> <span>信达生物</span> <span>替妥尤单抗</span> <span>眼科药物</span> <span>TED药物</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/10/feb9c6f8e2a2e9eaa9bb4f7f6a765c7c.png" alt="溶瘤病毒领域群雄逐鹿，Replimune RP系列管线引领免疫治疗新篇章"> <div class="tag color-2">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_39616" target="_blank">溶瘤病毒领域群雄逐鹿，Replimune RP系列管线引领免疫治疗新篇章</a></div> <div class="desc">溶瘤病毒市场虽已有产品上市但销量不佳，预计随着技术进步将快速增长。Replimune Group通过RPx平台开发系列溶瘤免疫疗法，其中RP1等管线在临床试验中表现积极。全球众多公司也在探索溶瘤疗法，未来有望成肿瘤治疗的重要手段。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药融圈</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-10</div> <div class="info-item"> <span>溶瘤病毒</span> <span>Replimune</span> <span>研发管线</span> <span>免疫治疗</span> <span>RP</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/27/c100bc367ffa1168398376cbcab183e8.png" alt="2025年最具潜力的新锐TOP10中药创新药！"> <div class="tag color-1">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_38524" target="_blank">2025年最具潜力的新锐TOP10中药创新药！</a></div> <div class="desc">近年来，中药新药研发进入爆发期，多家企业成为创新主力。政策推动中药新药重视临床价值，医保支付倾斜。自2020年以来，共有32个中药创新药品种成功上市或申报上市，本文筛选出10款值得关注的中药新药，涉及肿瘤、失眠、痛风等多个领域。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-27</div> <div class="info-item"> <span>TOP10</span> <span>中药创新药</span> <span>潜力药品</span> <span>新药研发</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/26/5edb9f8e1ada6109b01375d7371530de.png" alt="国内21家药企布局，IL-17A单抗赛道竞争激烈！荃信生物QX002N治疗强直性脊柱炎III期临床大捷"> <div class="tag color-1">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_38402" target="_blank">国内21家药企布局，IL-17A单抗赛道竞争激烈！荃信生物QX002N治疗强直性脊柱炎III期临床大捷</a></div> <div class="desc">2月24日，荃信生物宣布其自主研发的IL-17A单抗QX002N注射液治疗强直性脊柱炎的III期临床试验达主要终点，疗效显著且安全性良好。荃信生物专注于自身免疫及过敏性疾病生物疗法，国内IL-17A单抗竞争激烈，多家企业处于临床3期状态。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>生物药大时代</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-26</div> <div class="info-item"> <span>IL-17A单抗</span> <span>企业布局</span> <span>荃信生物</span> <span>QX002N注射液</span> <span>强直性脊柱炎</span> <span>临床试验</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/24/045ffd70f73b3875a9fbd72092f86857.png" alt="辉瑞全线退离基因治疗，罗氏等多家药企面临同样困境"> <div class="tag color-1">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_38141" target="_blank">辉瑞全线退离基因治疗，罗氏等多家药企面临同样困境</a></div> <div class="desc">近日，辉瑞终止B型血友病基因疗法Beqvez的开发和商业化，因其市场兴趣有限且未有患者接受商业化治疗。此外，辉瑞近年来多次撤回或终止基因疗法，包括镰状细胞贫血疗法、DMD基因疗法等。不仅辉瑞，罗氏、bluebird bio、CSL、BioMarin等公司也在退离基因治疗领域。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药事纵横</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-24</div> <div class="info-item"> <span>辉瑞</span> <span>基因治疗</span> <span>管线调整</span> <span>罗氏</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/21/2b7ca17a65e88804cf6ad59a70f5bd5b.png" alt="AI赋能医药行业，康龙化成、药明康德等药企纷纷布局AI医疗"> <div class="tag color-3">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_37929" target="_blank">AI赋能医药行业，康龙化成、药明康德等药企纷纷布局AI医疗</a></div> <div class="desc">AI医疗热潮兴起，康龙化成控股海心智惠等AI公司，整合高质量患者数据与AI技术平台提升新药开发效率。众多药企纷纷拥抱AI，积极投身于医药与AI融合的创新实践，AI为医药行业带来无限可能。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>生物药大时代</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-21</div> <div class="info-item"> <span>AI</span> <span>医药行业</span> <span>康龙化成</span> <span>药明康德</span> <span>AI医疗</span> <span>企业布局</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/21/4fa041b5e23b80b81d5af6bf4d847ba8.png" alt="吉利德科学2024财报亮眼：Biktarvy引领HIV治疗新篇章，营收突破287亿美元"> <div class="tag color-1">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_37928" target="_blank">吉利德科学2024财报亮眼：Biktarvy引领HIV治疗新篇章，营收突破287亿美元</a></div> <div class="desc">吉利德科学是一家生物制药公司，致力于药物革新以预防和治疗HIV、病毒性肝炎、癌症等疾病。2024财年，公司旗舰药物Biktarvy增长13%，全年营收287.54亿美元。吉利德在中国有商业运营，十三个药物获批，八个列入国家医保目录。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药融圈</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-21</div> <div class="info-item"> <span>吉利德科学</span> <span>Biktarvy</span> <span>抗HIV药物</span> <span>企业营收</span> <span>2024年财报</span> <span>管线布局</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/17/3f714723100f661f6e2e75f73cc261e4.png" alt="【盘点】2025年印度药企TOP10，引领全球仿制药市场"> <div class="tag color-3">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_37721" target="_blank">【盘点】2025年印度药企TOP10，引领全球仿制药市场</a></div> <div class="desc">印度制药业占全球疫苗供应50%以上，拥有3000家公司和10500个生产单位，贡献国内GDP的1.72%。印度十大制药公司中，Sun Pharma居首，2024年营收增长。印度制药业以仿制药为主，未来将进军创新药领域，预计行业将显著增长，面临挑战但也有机遇。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药事纵横</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-17</div> <div class="info-item"> <span>印度药企</span> <span>TOP10</span> <span>仿制药</span> <span>盘点</span> <span>2024年业绩</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/14/546aa74197ffb9299094e2a660db2d6e.png" alt="【盘点】国内57家布局干细胞疗法公司"> <div class="tag color-1">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_37709" target="_blank">【盘点】国内57家布局干细胞疗法公司</a></div> <div class="desc">干细胞疗法在生命科学领域备受瞩目，中国干细胞疗法市场规模预计将持续增长。多家国内企业已获批上市或进入后期临床阶段，稳步迈向商业化；同时，也有企业处于临床前研究或早期临床试验阶段，不断积累数据、推进研发。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>细胞基因治疗前沿</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-14</div> <div class="info-item"> <span>干细胞疗法</span> <span>生物医药企业</span> <span>药企盘点</span> <span>管线布局</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/10/76073e80c359dad27195e3c3ddc826c0.png" alt="【盘点】2024年小核酸领域重大事件"> <div class="tag color-2">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_37631" target="_blank">【盘点】2024年小核酸领域重大事件</a></div> <div class="desc">截至2024年，全球已有19款小核酸药物获批上市，治疗罕见病等领域。全球共有108种小核酸药物进入临床管线，市场规模增长迅速。2024年，小核酸领域药物获批、重大合作、融资事件及研发进展不断，深刻影响行业走向。国内小核酸研发虽起步晚但发展迅速。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-10</div> <div class="info-item"> <span>2024年盘点</span> <span>小核酸</span> <span>重大事件</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/07/f42956503f3466183caeb5be86bb85ee.png" alt="2024年上市CGT公司最新研发进展"> <div class="tag color-3">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_37510" target="_blank">2024年上市CGT公司最新研发进展</a></div> <div class="desc">2024年，CGT领域共有7家公司上市，其中5家通过IPO上市，2家与SPAC合并上市。这些公司涉及溶瘤免疫疗法、2型糖尿病和肥胖症基因疗法、细胞治疗等领域。此外，还有几家CGT公司已提交上市申请，为CGT领域注入新活力。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>细胞基因治疗前沿</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-07</div> <div class="info-item"> <span>上市公司</span> <span>2024年盘点</span> <span>CGT</span> <span>药物研发</span> <span>研发进展</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/06/e15f1ed77d892a4e0ddec7a34a8b2eb1.png" alt="诺和诺德2024年度财报出炉：司美格鲁肽与胰岛素驱动业绩飙升"> <div class="tag color-3">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_37506" target="_blank">诺和诺德2024年度财报出炉：司美格鲁肽与胰岛素驱动业绩飙升</a></div> <div class="desc">2月5日，丹麦诺和诺德公司公布2024年年报，全年营收、营业利润、净利润分别同比增长25%、25%、21%，盈利水平高达44.19%。公司业务以糖尿病与肥胖症护理为主，GLP-1和胰岛素是其主要收入来源。诺和诺德的高效性源于专注糖尿病、重视用户体验、充分利用产品和重视平台技术。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药事纵横</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-06</div> <div class="info-item"> <span>诺和诺德</span> <span>2024年财报</span> <span>司美格鲁肽</span> <span>胰岛素</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/05/b0f2768f987ca308f2f3a753518f58e4.png" alt="【盘点】2024年被拒批、延迟、终止的CGT疗法"> <div class="tag color-3">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_37399" target="_blank">【盘点】2024年被拒批、延迟、终止的CGT疗法</a></div> <div class="desc">2024年，CGT领域取得突破但也受挫，全球17款CGT疗法获批上市，但也有多款疗法被拒批、延迟审批或临床试验终止，如Abeona的EB-101、Rocket的Kresladi等，审批结果深刻影响患者治疗希望、企业发展及行业未来。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>细胞基因治疗前沿</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-05</div> <div class="info-item"> <span>2024年盘点</span> <span>CGT疗法</span> <span>药物审评审批</span> <span>临床试验</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202502/05/624d914c54b1cf9e6443008b708219cf.png" alt="【盘点】2024年跨国药企建厂投资"> <div class="tag color-3">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_37395" target="_blank">【盘点】2024年跨国药企建厂投资</a></div> <div class="desc">2024年，全球医药产业蓬勃发展，跨国药企纷纷投资建厂。在中国，赛诺菲、第一三共、礼来等跨国药企宣布投资建厂或升级产能。同时，诺和诺德、赛诺菲等也在其他国家投资。此外，迪哲医药、百济神州等国内企业也有建厂动作。这些布局将促进医药行业协同发展。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>生物药大时代</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-02-05</div> <div class="info-item"> <span>2024年盘点</span> <span>跨国药企</span> <span>药企建厂</span> <span>投资</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202412/23/de633f9ca1a9180b9a59c832f36be46b.png" alt="石家庄四药、科伦药业争抢甲磺酸沙非胺片国内首仿，帕金森病治疗市场迎新机遇"> <div class="tag color-1">赛道梳理</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/sdsl_33599" target="_blank">石家庄四药、科伦药业争抢甲磺酸沙非胺片国内首仿，帕金森病治疗市场迎新机遇</a></div> <div class="desc">12月20日，CDE官网公示，石家庄四药和科伦药业提交的甲磺酸沙非胺片仿制药上市申请获受理，有望夺得国内首仿。帕金森病市场规模持续增长，两家药企的加入将为百亿抗帕金森病药物市场注入新动力。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-12-23</div> <div class="info-item"> <span>石家庄四药</span> <span>科伦药业</span> <span>甲磺酸沙非胺片</span> <span>仿制药</span> <span>国内首仿</span> <span>帕金森病</span> </div> </div> </div> </li> </ul> <ul class="report-content content-trz"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/31/686ec74ed147301a11adf94ab18ecd9f.png" alt="CGT领域融资热潮持续，多家企业获资本青睐"> <div class="tag color-2">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_41792" target="_blank">CGT领域融资热潮持续，多家企业获资本青睐</a></div> <div class="desc">2025年3月，细胞与基因治疗（CGT）领域投融资与合作活动活跃。上海举办CGT产业化进展与项目融资路演对接会，10家上海企业展示技术优势与融资需求，获近20家投资机构关注。多家CGT企业完成融资，显示行业蓬勃发展。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>细胞基因治疗前沿</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-31</div> <div class="info-item"> <span>CGT</span> <span>投融资</span> <span>生物医药</span> <span>药企</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/26/44b2676d917cbe7aa251730d3175a2bc.png" alt="映恩生物IPO在即，多轮融资后估值近20亿，与全球药企合作总价值超60亿美元"> <div class="tag color-3">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_41322" target="_blank">映恩生物IPO在即，多轮融资后估值近20亿，与全球药企合作总价值超60亿美元</a></div> <div class="desc">映恩生物近日在港交所披露招股书，或将在香港IPO上市。公司由行业知名投资人朱忠远博士创立，致力于为癌症和自身免疫性疾病研发ADC创新药物。公司已完成四轮融资，并与多家全球领先合作伙伴订立合作交易，交易总价值逾60亿美元。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-26</div> <div class="info-item"> <span>映恩生物</span> <span>IPO</span> <span>投融资</span> <span>全球药企</span> <span>企业合作</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/04/1c09ab6f49b40687436b56b354fd58c9.png" alt="2024年医药健康投融资交易年报：全球热点与中国趋势大揭秘！"> <div class="tag color-3">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_39057" target="_blank">2024年医药健康投融资交易年报：全球热点与中国趋势大揭秘！</a></div> <div class="desc">2024年全球和中国医药健康投融资市场均呈现下降趋势，但美国和中国仍是投融资事件最多的国家。医药研发/制造、医疗器械等领域获投事件最多。合作协议成为最重要的交易主题，跨国交易和授权许可仍是中国企业的重要参与方式。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-04</div> <div class="info-item"> <span>医药健康行业</span> <span>投融资交易</span> <span>2024年报</span> <span>趋势分析</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202412/25/dad8de3286893be20c060669cc292126.png" alt="舒泰神子公司贝捷泰引入2亿投资，加速STSP-0601等三大核心项目研发"> <div class="tag color-1">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_33753" target="_blank">舒泰神子公司贝捷泰引入2亿投资，加速STSP-0601等三大核心项目研发</a></div> <div class="desc">2024年12月24日晚，舒泰神子公司贝捷泰拟增资扩股及股权转让，引入金易原力基金，增资1.33亿，转让股权6666.67万。金易原力基金共出资2亿，持股8.3916%。核心研发项目STSP-0601、STSA-1301、STSA-1503进展顺利。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药融圈</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-12-25</div> <div class="info-item"> <span>舒泰神</span> <span>贝捷泰</span> <span>投融资</span> <span>新药研发</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202412/11/2b1dd955fb26964f0bf86ab2de556bf6.png" alt="法伯新天宣布A2轮融资成功，亿元资金助力放射性药物研发"> <div class="tag color-1">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_32602" target="_blank">法伯新天宣布A2轮融资成功，亿元资金助力放射性药物研发</a></div> <div class="desc">12月9日，法伯新天医药宣布完成A2轮亿元融资，由同辐基金领投，资金将用于研发及放射性药物产业化基地建设。法伯新天专注分子影像诊断和放射性药物治疗，未来计划推出多款新管线产品。中国核医药市场规模持续增长，多家国内外企业纷纷入局。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>生物药大时代</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-12-11</div> <div class="info-item"> <span>法伯新天</span> <span>A2轮融资</span> <span>投融资</span> <span>放射性药物</span> <span>核医药市场</span> <span>药物研发</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202412/05/a4814ba08851b59b7d5645acdde72db1.png" alt="2024年医疗器械投融资盘点：超800起融资事件，多个区域赛道逆势坚挺！"> <div class="tag color-3">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_32302" target="_blank">2024年医疗器械投融资盘点：超800起融资事件，多个区域赛道逆势坚挺！</a></div> <div class="desc">2024年全球大健康领域投融资中，医疗器械类事件占比显著。中国医疗器械投融资事件数与创新药接近，且占比提高。全球医疗器械投融资事件波动，美国和中国是主要热点。中国江苏领跑，京沪苏粤多元并进。活跃机构特色投资，英赛飞影&层浪生物引领创新。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-12-05</div> <div class="info-item"> <span>2024年盘点</span> <span>医疗器械</span> <span>投融资</span> <span>启明创投</span> <span>英赛飞影</span> <span>层浪生物</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202411/15/a8e5c5aa5046efb68a69fe091b6633ff.png" alt="瑞科生物获扬子江药业注资，新款带状疱疹疫苗研发提速"> <div class="tag color-1">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_29719" target="_blank">瑞科生物获扬子江药业注资，新款带状疱疹疫苗研发提速</a></div> <div class="desc">2024年11月11日，港股疫苗公司瑞科生物宣布定向发行不超过1.43亿股内资股给扬子江药业集团，每股5.59元人民币，募资约8亿元，并获3.8%年利率借款。瑞科生物正研发带状疱疹疫苗REC610，现已启动中国III期临床研究。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药融圈</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-11-15</div> <div class="info-item"> <span>瑞科生物</span> <span>扬子江药业</span> <span>投融资</span> <span>带状疱疹疫苗</span> <span>新药研发</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202411/13/90e0adeb6574a59eb88b6d29832142b9.png" alt="莱芒生物超亿元A轮融资成功，加速代谢增强型CAR-T疗法研发"> <div class="tag color-1">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_29418" target="_blank">莱芒生物超亿元A轮融资成功，加速代谢增强型CAR-T疗法研发</a></div> <div class="desc">莱芒生物近期完成超亿元A轮融资首关，由富汇创投领投，资金将用于极低剂量代谢增强型CAR-T药物IND申报等。此前，公司已获近亿元天使轮融资及多项资助。其代谢增强型CAR-T疗法在临床试验中取得显著疗效。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>细胞基因治疗前沿</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-11-13</div> <div class="info-item"> <span>莱芒生物</span> <span>A轮融资</span> <span>代谢增强型CAR-T疗法</span> <span>药物研发</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202411/11/9b284a5d43ed7482c5a0f5ca3a43f9dc.png" alt="康缘药业：2.7亿收购中新医药，抢滩代谢及神经系统疾病新药市场"> <div class="tag color-1">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_29137" target="_blank">康缘药业：2.7亿收购中新医药，抢滩代谢及神经系统疾病新药市场</a></div> <div class="desc">康缘药业计划以2.7亿收购中新医药100%股权，中新医药专注代谢性及神经系统疾病新药研发，已有4个创新药6个临床批件。康缘集团与南京康竹分别持有中新医药70%和30%股权，对应转让价款分别为1.89亿和0.81亿。康缘药业拟将中新医药研发团队、管线及平台纳入上市公司，加速研发成果产业化。双方还设定了对赌条款。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药融圈</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-11-11</div> <div class="info-item"> <span>康缘药业</span> <span>中新医药</span> <span>企业收购</span> <span>新药研发</span> <span>新药管线产业化</span> <span>代谢性疾病</span> <span>神经系统疾病</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202411/05/2783dd0a9582f9fbd9afcd5f97aeec0e.png" alt="信达生物终止高额股权认购协议！股价回涨超12%"> <div class="tag color-1">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_28363" target="_blank">信达生物终止高额股权认购协议！股价回涨超12%</a></div> <div class="desc">11月3日，信达生物宣布终止10月25日与Lostrancos的认购协议，因其受到股东反馈及不同看法，终止交易符合公司及股东利益。此前，信达生物宣布Lostrancos认购Fortvita股权被市场解读为贱卖。公司股价连跌四天后，11月4日开盘大涨超12%。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>生物药大时代</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-11-05</div> <div class="info-item"> <span>信达生物</span> <span>股权认购协议</span> <span>股价</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202410/28/ebb32591c3f5f411e8461178e7cdcd3f.png" alt="默沙东13亿美金收购Modifi，瞄准难治性脑肿瘤新疗法KL-50"> <div class="tag color-1">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_27260" target="_blank">默沙东13亿美金收购Modifi，瞄准难治性脑肿瘤新疗法KL-50</a></div> <div class="desc">近日，默沙东斥资13亿美元收购Modifi Biosciences，获其实验性癌症疗法使用权，预付3000万美元。Modifi开发的治疗方法KL-50旨在治疗脑肿瘤。默沙东正寻求新药以弥补Keytruda收入损失。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-10-28</div> <div class="info-item"> <span>默沙东</span> <span>Modifi Biosciences</span> <span>企业收购</span> <span>脑肿瘤</span> <span>KL-50</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202410/28/cba99c7f345a034ac7bc24ceec389f6f.png" alt="三星生物签下12.4亿美元大单，CDMO业务持续扩张"> <div class="tag color-3">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_27258" target="_blank">三星生物签下12.4亿美元大单，CDMO业务持续扩张</a></div> <div class="desc">10月22日，三星生物与亚洲制药公司签订12.4亿美元大单，有效期至2037年。2024年三星生物已签多份重要合同，累计合同额超130亿美元，并计划扩大工厂规模，预计2032年产能将增至720KL。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>生物药大时代</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-10-28</div> <div class="info-item"> <span>三星生物</span> <span>CDMO业务</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202410/28/15635211098f35d7ed4048fcc498f44b.png" alt="恒瑞医药2024年前三季度业绩亮眼，净利增32.98%或香港二次上市"> <div class="tag color-3">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_27257" target="_blank">恒瑞医药2024年前三季度业绩亮眼，净利增32.98%或香港二次上市</a></div> <div class="desc">10月24日晚，恒瑞医药发布2024年前三季度业绩报告，营收和净利润均增长。三季度业绩增长主要由于收到MerckHealthcare的许可首付款。公司前三季度研发费用大增。此外，恒瑞医药正考虑在香港第二上市，但尚未确定具体方案。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>Pharma CMC</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-10-28</div> <div class="info-item"> <span>恒瑞医药</span> <span>业绩</span> <span>二次上市</span> <span>企业上市</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202410/22/38a945bfbcc6baeca20a48111d7a2334.png" alt="炫景生物、士泽生物融资超亿，加速CGT疗法研发与临床应用"> <div class="tag color-2">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_8646" target="_blank">炫景生物、士泽生物融资超亿，加速CGT疗法研发与临床应用</a></div> <div class="desc">10月21日，炫景生物和士泽生物分别宣布完成超亿元融资，用于CGT疗法研发。炫景生物专注小核酸药物，士泽生物开发iPS衍生细胞药治疗神经系统疾病。CGT领域持续热门，2024年前三季度国内融资企业超60家。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药（原药融云）</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-10-22</div> <div class="info-item"> <span>炫景生物</span> <span>士泽生物</span> <span>投融资</span> <span>CGT疗法</span> <span>药物研发</span> <span>临床应用</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202410/22/0805d27814397e391c62a7981c4f552a.png" alt="四川双马斥资15.96亿收购深圳健元医药，拓展多肽类原料药业务"> <div class="tag color-1">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_8645" target="_blank">四川双马斥资15.96亿收购深圳健元医药，拓展多肽类原料药业务</a></div> <div class="desc">10月21日晚，四川双马公告称，拟15.96亿元收购深圳健元92.1745%股权，以增强生物医药业务。深圳健元主营多肽类原料药等，业绩良好。四川双马近年来转型产业投资及管理，重点布局科技创新领域。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>生物药大时代</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-10-22</div> <div class="info-item"> <span>四川双马</span> <span>健元医药</span> <span>企业收购</span> <span>多肽类原料药</span> <span>业务拓展</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202406/26/104bb5c7655c142d284dc742106cbb70.png" alt="安帝康生物获超2亿元A轮融资，加速抗流感新药玛氘诺沙韦的研发与商业化"> <div class="tag color-3">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_8029" target="_blank">安帝康生物获超2亿元A轮融资，加速抗流感新药玛氘诺沙韦的研发与商业化</a></div> <div class="desc">安帝康生物获超2亿元A轮融资，由先声药业、华金投资等领投，将加速流感新药玛氘诺沙韦的研发与商业化进程。该药在治疗青少年及成人流感方面显示出色疗效，并启动儿童患者的临床试验。公司专注于呼吸感染和疼痛领域创新药物研发，拥有多款创新药物管线。本轮融资将助力安帝康生物推进创新药物研发，为患者带来新治疗选择。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药融圈</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-06-26</div> <div class="info-item"> <span>安帝康生物</span> <span>A轮融资</span> <span>药物研发</span> <span>商业化</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202404/28/6261d7d0e939be8f4b9e9d81a8c56c13.png" alt="国内核药再现大笔融资，是值得押注的赛道吗？"> <div class="tag color-2">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_7794" target="_blank">国内核药再现大笔融资，是值得押注的赛道吗？</a></div> <div class="desc">由于放射性，使核药这类品种成为特殊高门槛的存在：生产、研究开发、临床试验、使用都受到严格监管。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药融圈</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-04-28</div> <div class="info-item"> <span>核药</span> <span>投融资</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202404/28/d1791b74fd99cc8e24391104d1474d64.png" alt="日本大财团三井物产和乐敦制药，47亿收购百年中医药品牌余仁生"> <div class="tag color-2">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_7795" target="_blank">日本大财团三井物产和乐敦制药，47亿收购百年中医药品牌余仁生</a></div> <div class="desc">药融云数据监测显示：2024年4月初，日本巨头三井物产(Mitsui & Co)与乐敦制药(Rohto Pharmaceutical Co.)公布，将成立特殊目的合资公司收购余仁生国际(Eu Yan Sang International)100%股权</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药融圈</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-04-28</div> <div class="info-item"> <span>三井物产</span> <span>乐敦制药</span> <span>余仁生</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202404/23/bab3a1c858565bd202ef84ffbe4a20ca.png" alt="2024Q1季度：6家CGT公司上市"> <div class="tag color-1">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_7762" target="_blank">2024Q1季度：6家CGT公司上市</a></div> <div class="desc">2024年1-3月，据不完全统计，共6家CGT公司上市，其中4家通过IPO上市，2家通过与SPAC公司合并上市。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>细胞基因治疗前沿</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-04-23</div> <div class="info-item"> <span>IPO上市</span> <span>细胞免疫疗法</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202404/18/2f30fe2d780c83ed3c728367f5a6a510.png" alt="2024年4月国内CGT投融资盘点"> <div class="tag color-3">投融资</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/trz_7747" target="_blank">2024年4月国内CGT投融资盘点</a></div> <div class="desc">截至今日，2024年4月国内细胞与基因治疗（CGT）公司迎来多起投融资，融资金额超5亿元，其中有3家融资金额超亿元，分别是羿尊生物、昂拓生物、跃赛生物，让我们一起来看看这些公司。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>细胞基因治疗前沿</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2024-04-18</div> <div class="info-item"> <span>CGT疗法</span> <span>融资</span> </div> </div> </div> </li> </ul> <ul class="report-content content-zcsp"> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/07/961dea753c12c48ac5d327b34738f087.png" alt="立方制药帕利哌酮缓释片获批上市，抗精神病药销售格局与竞争解析"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_42539" target="_blank">立方制药帕利哌酮缓释片获批上市，抗精神病药销售格局与竞争解析</a></div> <div class="desc">立方制药申报的4类仿制药帕利哌酮缓释片（6mg、3mg）获批生产并视同过评，适用于成人及12-17岁青少年精神分裂症治疗，立方制药为第5家获批上市企业。原研为杨森制药，近年来该药成为抑郁症一线用药，进入医保。从2024年前三季度销售额竞争格局看，首仿豪森药业占比56%，杨森制药占比40%。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-07</div> <div class="info-item"> <span>立方制药</span> <span>帕利哌酮缓释片</span> <span>药品审评审批</span> <span>抗精神病药物</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/f715468a791b78e0b0f9354a5cbfce03.png" alt="抗病毒药物盐酸伐昔洛韦片热销，宜昌人福药业等六家企业过评"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_42195" target="_blank">抗病毒药物盐酸伐昔洛韦片热销，宜昌人福药业等六家企业过评</a></div> <div class="desc">4月1日，宜昌人福药业提交的原6类仿制药盐酸伐昔洛韦片获批并通过一致性评价，成为国产第6家过评企业。盐酸伐昔洛韦片具有较好市场潜力，人福药业2025年至今已有7款品种过评。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-03</div> <div class="info-item"> <span>抗病毒药物</span> <span>盐酸伐昔洛韦片</span> <span>宜昌人福药业</span> <span>仿制药</span> <span>药品审评审批</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/02/ad7db8747dadbe11f0e9abf97d9e1540.png" alt="扬子江药业获批泊马度胺胶囊，国内第三家仿制药企入局"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_42082" target="_blank">扬子江药业获批泊马度胺胶囊，国内第三家仿制药企入局</a></div> <div class="desc">3月31日，扬子江药业提交的泊马度胺胶囊仿制药上市申请获NMPA批准，成为国内第三家获批企业。泊马度胺是一种治疗血液肿瘤的免疫调节剂，全球销售额快速增长。原研产品未在国内上市，但国内已有三家企业仿制药视同过评。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-02</div> <div class="info-item"> <span>扬子江药业</span> <span>泊马度胺胶囊</span> <span>仿制药</span> <span>药品审评审批</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202504/01/a704c17d511ce81afc20662c5318169c.png" alt="氯化钙注射液市场持续升温，天成药业首家过评引领高质量发展"> <div class="tag color-1">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_41941" target="_blank">氯化钙注射液市场持续升温，天成药业首家过评引领高质量发展</a></div> <div class="desc">近日，河北天成药业成为国内首家通过氯化钙注射液一致性评价的企业。氯化钙注射液是治疗钙缺乏等疾病的首选药，市场需求持续增长，2023年市场规模突破2亿元，天成药业占据76%市场份额。随着多家企业提交上市申请，未来市场竞争或将加剧。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-04-01</div> <div class="info-item"> <span>氯化钙注射液</span> <span>天成药业</span> <span>首家过评</span> <span>药物审评审批</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/24/88e0972c14c498a6814f3d4b3abfba92.png" alt="国内IgA肾病治疗新突破！石药集团中诺药业抢滩布地奈德肠溶胶囊市场，有望拿下首仿"> <div class="tag color-1">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_40971" target="_blank">国内IgA肾病治疗新突破！石药集团中诺药业抢滩布地奈德肠溶胶囊市场，有望拿下首仿</a></div> <div class="desc">石药集团中诺药业提交的布地奈德肠溶胶囊上市申请已获受理，有望拿下国内首仿。布地奈德肠溶胶囊是全球首款针对IgA肾病的对因治疗药物。此前，布地奈德主要用于呼吸系统疾病，但集采后销售额大幅下降。此次仿制药受理为IgA肾病治疗提供新选择。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-24</div> <div class="info-item"> <span>IgA肾病</span> <span>石药集团中诺药业</span> <span>布地奈德肠溶胶囊</span> <span>仿制药</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/21/afc44c8cc00f40cb21d9e5350be0f452.png" alt="自免药王度普利尤单抗新适应症拟优先审评，中国市场潜力再扩大"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_40711" target="_blank">自免药王度普利尤单抗新适应症拟优先审评，中国市场潜力再扩大</a></div> <div class="desc">3月19日，CDE官网公示，赛诺菲提交度普利尤单抗（达必妥）新适应症大疱性类天疱疮上市申请拟优先审评，为其在华获批第五项适应症。度普利尤单抗全球及中国市场销售表现优异，新适应症审评将进一步扩大其市场潜力。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-21</div> <div class="info-item"> <span>自免药物</span> <span>度普利尤单抗</span> <span>新适应症</span> <span>优先审评</span> <span>大疱性类天疱疮</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/18/f17dd4ddffaf13cf15fe2228e646fb4c.png" alt="恒瑞医药新药富马酸泰吉利定注射液获批新适应症，国产1类阿片镇痛药市场迎新机遇"> <div class="tag color-3">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_40349" target="_blank">恒瑞医药新药富马酸泰吉利定注射液获批新适应症，国产1类阿片镇痛药市场迎新机遇</a></div> <div class="desc">3月14日，恒瑞医药的1类新药富马酸泰吉利定注射液获批新增骨科手术后中重度疼痛适应症，并与原适应症合并为“术后中重度疼痛治疗”。作为首个国产1类阿片镇痛药，它通过特异性结合μ阿片受体镇痛。该药品纳入2024版国家医保目录后，预计市场占有率和患者可及性将大幅提升。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-18</div> <div class="info-item"> <span>恒瑞医药</span> <span>新适应症获批</span> <span>富马酸泰吉利定注射液</span> <span>1类新药</span> <span>阿片镇痛药</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/17/9cfc88db3c4b65313bc06b4a7373026c.png" alt="石家庄四药领跑大输液行业，心脏急救药盐酸肾上腺素注射液获批上市"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_40232" target="_blank">石家庄四药领跑大输液行业，心脏急救药盐酸肾上腺素注射液获批上市</a></div> <div class="desc">3月14日，石家庄四药提交的仿制药盐酸肾上腺素注射液获批上市并通过一致性评价，该药品主要用于心脏骤停抢救等。目前，石家庄四药已有119个品种过评，其中今年已获批9个品种。该集团还布局了肾上腺素系列产品线。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-17</div> <div class="info-item"> <span>石家庄四药</span> <span>心脏急救药</span> <span>盐酸肾上腺素注射液</span> <span>获批上市</span> <span>输液行业</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/17/b085b592bdd305c76cb331110eeec64f.png" alt="中美双重突破性疗法认证！伊那利塞联合疗法获批治疗耐药乳腺癌"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_40228" target="_blank">中美双重突破性疗法认证！伊那利塞联合疗法获批治疗耐药乳腺癌</a></div> <div class="desc">2025年3月11日，NMPA批准罗氏制药的伊那利塞联合哌柏西利和氟维司群，用于内分泌治疗耐药、PIK3CA突变、HR+/HER2-的局部晚期或转移性乳腺癌患者。伊那利塞是中国首个高选择性PI3Kα抑制剂，基于INAVO120研究，显著延长患者PFS，获中美双重突破性疗法认证。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>药融圈</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-17</div> <div class="info-item"> <span>伊那利塞</span> <span>突破性疗法</span> <span>乳腺癌</span> <span>联合疗法</span> <span>药物审评审批</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/14/97046818bef01c805d7386b1bd56ad2e.png" alt="凝血因子Xa抑制剂市场争夺激烈，扬子江药业甲苯磺酸艾多沙班片获批上市"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_40094" target="_blank">凝血因子Xa抑制剂市场争夺激烈，扬子江药业甲苯磺酸艾多沙班片获批上市</a></div> <div class="desc">3月10日，扬子江药业旗下南京海陵药业提交的仿制药甲苯磺酸艾多沙班片获批上市并视同过评，成为第8家获批企业。甲苯磺酸艾多沙班片销售额快速增长，原研药占主导地位，扬子江药业今年已有两款药品过评，持续丰富产品线。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-14</div> <div class="info-item"> <span>扬子江药业</span> <span>甲苯磺酸艾多沙班片</span> <span>获批上市</span> <span>凝血因子Xa抑制剂</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/13/90d1398e7c78c11ac0b526aa298f5edb.png" alt="山东新华制药成第4家！5亿+止痛药喷他佐辛注射液获批上市"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_39993" target="_blank">山东新华制药成第4家！5亿+止痛药喷他佐辛注射液获批上市</a></div> <div class="desc">3月10日，山东新华制药成为第4家获批并过评喷他佐辛注射液的药企，该注射液兼具阿片受体激动与拮抗特性，用于缓解慢性重度疼痛等。目前原研产品未进中国市场，山东新华制药今年已有3款品种过评。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-13</div> <div class="info-item"> <span>山东新华制药</span> <span>喷他佐辛注射液</span> <span>获批上市</span> <span>药品审评审批</span> <span>止痛药</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/13/5dab01f187cb4039453a6637f61693cd.png" alt="诺华IL-17A抑制剂司库奇尤单抗在中国获批第五项适应症，为化脓性汗腺炎患者提供全新治疗选择"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_39992" target="_blank">诺华IL-17A抑制剂司库奇尤单抗在中国获批第五项适应症，为化脓性汗腺炎患者提供全新治疗选择</a></div> <div class="desc">3月12日，诺华宣布其生物制剂司库奇尤单抗获得中国国家药品监督管理局批准，用于治疗中重度化脓性汗腺炎的成人患者。这是司库奇尤单抗在中国获批的第五个适应症，此次批准为化脓性汗腺炎患者提供了新的治疗选择，有望改善他们的生活质量。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-13</div> <div class="info-item"> <span>诺华</span> <span>司库奇尤单抗</span> <span>IL-17A抑制剂</span> <span>新适应症获批</span> <span>化脓性汗腺炎</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/12/88e4023239445cd9bd6c9afe13f70238.png" alt="艾伯维重磅IL-23抑制剂利生奇珠单抗在中国获批上市，克罗恩病患者迎新希望！"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_39851" target="_blank">艾伯维重磅IL-23抑制剂利生奇珠单抗在中国获批上市，克罗恩病患者迎新希望！</a></div> <div class="desc">3月10日，艾伯维研发的利生奇珠单抗注射液获批在中国上市，用于治疗对传统治疗应答不足的中重度活动性克罗恩病成年患者。利生奇珠单抗是一种IL-23抑制剂，中国IL抑制剂市场规模大幅增长。艾伯维有望凭借强大销售能力使新药快速放量。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-12</div> <div class="info-item"> <span>自免领域</span> <span>艾伯维</span> <span>IL-23抑制剂</span> <span>利生奇珠单抗</span> <span>获批上市</span> <span>克罗恩病</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/11/04efd83b5f6d065256227d091cfd5bbe.png" alt="四川普锐特药业成国产沙美特罗替卡松吸入粉雾剂第2家过评企业，进一步挑战进口垄断"> <div class="tag color-1">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_39749" target="_blank">四川普锐特药业成国产沙美特罗替卡松吸入粉雾剂第2家过评企业，进一步挑战进口垄断</a></div> <div class="desc">3月10日，四川普锐特药业提交的沙美特罗替卡松吸入粉雾剂仿制药获批并过评，成为该产品国产第2家。该产品原研自GSK，是治疗哮喘与慢阻肺的重要药物。目前，国内吸入制剂市场仍被进口厂商主导，普锐特药业已有10款品种过评。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-11</div> <div class="info-item"> <span>四川普锐特药业</span> <span>沙美特罗替卡松吸入粉雾剂</span> <span>仿制药</span> <span>哮喘</span> <span>慢阻肺</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/11/14e1b7d56dfefbb7a4b5d4afcec65393.png" alt="科伦博泰芦康沙妥珠单抗：TROP2靶向ADC新适应症获批，助力非小细胞肺癌治疗"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_39748" target="_blank">科伦博泰芦康沙妥珠单抗：TROP2靶向ADC新适应症获批，助力非小细胞肺癌治疗</a></div> <div class="desc">3月10日，NMPA批准科伦博泰的芦康沙妥珠单抗新适应症上市，用于EGFR-TKI和含铂化疗治疗失败的局部晚期或转移性EGFR突变非小细胞肺癌。该产品通过靶向TROP2诱导肿瘤细胞DNA损伤，已在中国获批用于三阴性乳腺癌治疗。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-11</div> <div class="info-item"> <span>科伦博泰</span> <span>芦康沙妥珠单抗</span> <span>TROP2</span> <span>ADC药物</span> <span>新适应症获批</span> <span>非小细胞肺癌</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/10/a9397b26e5bf821125d930c7e7038731.png" alt="人福医药首款1类新药HW201877胶囊获批临床，专攻炎症性肠病"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_39619" target="_blank">人福医药首款1类新药HW201877胶囊获批临床，专攻炎症性肠病</a></div> <div class="desc">人福医药旗下武汉研发中心的新药HW201877胶囊获批临床，用于炎症性肠病治疗，填补市场空白。该公司在创新药领域深耕细作，已有超10款1类新药获批临床，并成功取得两款新药的临床试验批准，未来有望提供更多优质治疗选择。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-10</div> <div class="info-item"> <span>人福医药</span> <span>HW201877胶囊</span> <span>1类新药</span> <span>获批临床</span> <span>炎症性肠病</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/07/6cb667d9459dc4752b80178c81152fb4.png" alt="复星医药新一代ALK抑制剂丁二酸复瑞替尼上市申请获受理，非小细胞肺癌治疗有望迎新突破"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_39471" target="_blank">复星医药新一代ALK抑制剂丁二酸复瑞替尼上市申请获受理，非小细胞肺癌治疗有望迎新突破</a></div> <div class="desc">3月6日，复星万邦提交的1类新药丁二酸复瑞替尼胶囊上市申请获受理，为新一代ALK/ROS1抑制剂，拟用于ALK突变阳性非小细胞肺癌治疗。预计将成为第四款国产ALK抑制剂上市，市场竞争将加剧。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-07</div> <div class="info-item"> <span>复星医药</span> <span>ALK抑制剂</span> <span>丁二酸复瑞替尼</span> <span>上市申请</span> <span>非小细胞肺癌</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/07/3d898e0cd95e646eec5ed45f0505fa8d.png" alt="翰森制药B7-H4 ADC药物HS-20089启动III期临床试验，剑指铂耐药卵巢癌治疗新纪元"> <div class="tag color-1">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_39470" target="_blank">翰森制药B7-H4 ADC药物HS-20089启动III期临床试验，剑指铂耐药卵巢癌治疗新纪元</a></div> <div class="desc">翰森制药已启动创新药物HS-20089（B7-H4 ADC药物）的III期临床试验，旨在评估其治疗铂耐药复发卵巢癌等癌症的疗效与安全性。此前早期临床试验数据表现良好，葛兰素史克已与翰森制药达成战略合作。HS-20089目前处于B7-H4 ADC药物研发前列。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-07</div> <div class="info-item"> <span>翰森制药</span> <span>B7-H4</span> <span>HS-20089</span> <span>ADC药物</span> <span>临床试验</span> <span>卵巢癌</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/06/c96d5d414813a780fe3900ad35e3c967.png" alt="百济神州创新ADC药物BGB-C354获批临床，携手替雷利珠单抗攻克晚期实体瘤"> <div class="tag color-2">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_39337" target="_blank">百济神州创新ADC药物BGB-C354获批临床，携手替雷利珠单抗攻克晚期实体瘤</a></div> <div class="desc">百济神州自主研发的1类新药注射用BGB-C354，针对B7H3靶点，已获得CDE新的临床试验默示许可，将联合替雷利珠单抗治疗晚期实体瘤。此前已在中国获批进入临床研究，此次批准将进一步推动其研究进程，为患者带来新治疗希望。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-06</div> <div class="info-item"> <span>百济神州</span> <span>ADC新药</span> <span>BGB-C354</span> <span>替雷利珠单抗</span> <span>获批临床</span> <span>晚期实体瘤</span> </div> </div> </div> </li> <li class="report-item" onclick="targetBlank(this)"> <div class="img"> <img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/covers/202503/05/3f6f54d5b7883e7260d880c17e2466b6.png" alt="两大重磅新药上市申请遭驳回，齐鲁制药和乐普生物双双受挫！"> <div class="tag color-3">注册审批</div> </div> <div class="report-detail"> <div class="title"><a onclick="return false" class="item-title" href="/zixun/zcsp_39209" target="_blank">两大重磅新药上市申请遭驳回，齐鲁制药和乐普生物双双受挫！</a></div> <div class="desc">2025年3月3日，国家药监局公布当日药品通知件送达信息，齐鲁制药的艾帕洛利单抗注射液单方申请未成功，复方制剂已获批；乐普生物的注射用维贝柯妥塔单抗（MRG003）因需补充资料撤回申请后重新递交。新药研发面临多重风险，需实时跟进竞品进度，动态调整申报策略。</div> <div class="info"> <div class="info-item"><i class="icon iconfont icon-menhu-zuozhe"></i>摩熵医药</div> <div class="info-item"><i class="icon iconfont icon-a-menhu-shijian4"></i>2025-03-05</div> <div class="info-item"> <span>齐鲁制药</span> <span>乐普生物</span> <span>新药研发</span> <span>药品审评审批</span> <span>上市申请</span> </div> </div> </div> </li> </ul> <div class="load-more"><span onclick="getMoreInformation()">加载更多</span></div> </div> <div class="right"> <div class="model-content content-1 active-content"> <div class="model"> <div class="component-card list-card-1" id="newData-card" style="--color: #FF8A1E;"> <div class="title"> <h3 class="title-name">最新临床数据</h3> <div class="more"><a href="https://www.pharnexcloud.com/data/lcsy">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="swiper" style="height: 330px;"> <ul class="swiper-wrapper list"> </ul> </div> </div> </div> <script> let count = 5 getCardData('newData').then(() => { new Swiper("#newData-card .swiper", { loop: true, slidesPerView: +count, loopFillGroupWithBlank: true, loopAdditionalSlides: +count, direction: 'vertical', // 设置轮播方向 grabCursor: true, freeMode: false, speed: 3000, autoplay: { delay: 0, disableOnInteraction: false } }) }) </script> </div> <div class="model"> <div class="component-card list-card-2" id="newDrug-card" style="--color: #4282FF;"> <div class="title"> <h3 class="title-name">全球批准上市新药统计</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://data.pharnexcloud.com/1/table/44?from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="swiper"> <ul class="swiper-wrapper list"> </ul> </div> </div> </div> <script> getCardData('newDrug').then(() => { new Swiper("#newDrug-card .swiper", { loop: true, slidesPerView: 5, loopFillGroupWithBlank: true, loopAdditionalSlides: 5, direction: 'vertical', // 设置轮播方向 grabCursor: true, freeMode: false, speed: 3000, autoplay: { delay: 0, disableOnInteraction: false } }) }) </script> </div> </div> <div class="model-content content-sdfx content-sdsl"> <div class="model"> <div class="component-card chart-card" id="therapyArea-card" style="--color: #4282FF;"> <div class="title"> <h3 class="title-name">全球新药治疗领域统计</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://data.pharnexcloud.com/1/table/44?from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="chart-content"> <div class="chart" id="therapyArea-chart"></div> </div> <div class="footer-data"> <span>数据来源：<span class="source"></span></span> <span class="time">更新时间：<span class="date"></span></span> </div> </div> </div> <script type="text/javascript"> getBarChartData(1) </script> </div> <div class="model"> <div class="component-card chart-card" id="target-card" style="--color: #07AEA0;"> <div class="title"> <h3 class="title-name">全球新药靶点统计</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://data.pharnexcloud.com/1/table/44?from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="chart-content"> <div class="chart" id="target-chart"></div> </div> <div class="footer-data"> <span>数据来源：<span class="source"></span></span> <span class="time">更新时间：<span class="date"></span></span> </div> </div> </div> <script type="text/javascript"> getBarChartData(3) </script> </div> </div> <div class="model-content content-zcsp"> <div class="model"> <div class="component-card chart-card" id="drugReview-card" style="--color: #FF8A1E;"> <div class="title"> <h3 class="title-name">中国药品审评</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://data.pharnexcloud.com/1/table/58?from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="chart-content"> <div class="chart" id="drugReview-chart"></div> </div> <div class="footer-data"> <span>数据来源：<span class="source"></span></span> <span class="time">更新时间：<span class="date"></span></span> </div> </div> </div> <script type="text/javascript"> getStackedLineChartData(1) </script> </div> <div class="model"> <div class="component-card chart-card" id="FDA-card" style="--color: #4282FF;"> <div class="title"> <h3 class="title-name">美国FDA批准药品</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://data.pharnexcloud.com/7/table/153?from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="chart-content"> <div class="chart" id="FDA-chart"></div> </div> <div class="footer-data"> <span>数据来源：<span class="source"></span></span> <span class="time">更新时间：<span class="date"></span></span> </div> </div> </div> <script type="text/javascript"> getStackedBarChartData(1) </script> </div> </div> <div class="model-content content-zcfg"> <div class="model"> <div class="component-card chart-card" id="collect-card" style="--color: #4282FF;"> <div class="title"> <h3 class="title-name">第九批国家集中采购品种</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://data.pharnexcloud.com/4/table/253?from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="chart-content"> <div class="chart" id="collect-chart"></div> </div> <div class="footer-data"> <span>数据来源：<span class="source"></span></span> <span class="time">更新时间：<span class="date"></span></span> </div> </div> </div> <script type="text/javascript"> getBarChartData(2) </script> </div> <div class="model"> <div class="component-card chart-card" id="directory-card" style="--color: #07AEA0;"> <div class="title"> <h3 class="title-name">医保目录（2023）</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://data.pharnexcloud.com/6/table/33?from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="chart-content"> <div class="chart" id="directory-chart"></div> </div> <div class="footer-data"> <span>数据来源：<span class="source"></span></span> <span class="time">更新时间：<span class="date"></span></span> </div> </div> </div> <script type="text/javascript"> getBarChartData(4) </script> </div> </div> <div class="model-content content-gpjx"> <div class="model"> <div class="component-card list-card-2" id="CDE-card" style="--color: #FF5757;"> <div class="title"> <h3 class="title-name">CDE药品承办信息</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://data.pharnexcloud.com/1/table/58?from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="swiper"> <ul class="swiper-wrapper list"> </ul> </div> </div> </div> <script> getCardData('CDE').then(() => { new Swiper("#CDE-card .swiper", { loop: true, slidesPerView: 5, loopFillGroupWithBlank: true, loopAdditionalSlides: 5, direction: 'vertical', // 设置轮播方向 grabCursor: true, freeMode: false, speed: 3000, autoplay: { delay: 0, disableOnInteraction: false } }) }) </script> </div> <div class="model"> <div class="component-card list-card-2" id="newPass-card" style="--color: #4282FF;"> <div class="title"> <h3 class="title-name">最新一致性过评品种</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://data.pharnexcloud.com/2/table/25?from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="swiper"> <ul class="swiper-wrapper list"> </ul> </div> </div> </div> <script> getCardData('newPass').then(() => { new Swiper("#newPass-card .swiper", { loop: true, slidesPerView: 5, loopFillGroupWithBlank: true, loopAdditionalSlides: 5, direction: 'vertical', // 设置轮播方向 grabCursor: true, freeMode: false, speed: 3000, autoplay: { delay: 0, disableOnInteraction: false } }) }) </script> </div> </div> <div class="model-content content-trz"> <div class="model"> <div class="component-card chart-card" id="investment-card" style="--color: #FF5757;"> <div class="title"> <h3 class="title-name">资本透视</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://data.pharnexcloud.com/4/table/211?from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="chart-content"> <div class="chart" id="investment-chart"></div> </div> <div class="footer-data"> <span>数据来源：<span class="source"></span></span> <span class="time">更新时间：<span class="date"></span></span> </div> </div> </div> <script type="text/javascript"> getStackedLineChartData(2) </script> </div> <div class="model"> <div class="component-card list-card-2" id="newFinance-card" style="--color: #07AEA0;"> <div class="title"> <h3 class="title-name">最新投融资事件</h3> <div class="more"><a href="https://www.pharnexcloud.com/trz">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="swiper"> <ul class="swiper-wrapper list"> </ul> </div> </div> </div> <script> getCardData('newFinance').then(() => { new Swiper("#newFinance-card .swiper", { loop: true, slidesPerView: 5, loopFillGroupWithBlank: true, loopAdditionalSlides: 5, direction: 'vertical', // 设置轮播方向 grabCursor: true, freeMode: false, speed: 3000, autoplay: { delay: 0, disableOnInteraction: false } }) }) </script> </div> </div> <div class="images"> <a onclick="advertAddClick(3)" target="_blank" rel="nofollow" href="https://www.pharnexcloud.com/activity/newProduct" ><img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/ad_images/202410/22/de943d9fdac72cc3e066979bd81b9578.jpg" alt="新品发布"></a> </div> <div class="model"> <div class="component-card chart-card shop" id="hospitalDrug-card" style="--color: #4282FF;"> <div class="title"> <h3 class="title-name">2023年全国医院销售(全终端)数据</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://vip.pharnexcloud.com/database/yyqzdsale?auto=1&from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="chart-content"> <div class="yAxis">药品名称</div> <div class="xAxis">销售额(亿元)</div> <div class="chart" id="hospitalDrug-chart"></div> </div> <div class="footer-data"> <span>数据来源：<span class="source"></span></span>  </div> </div> </div> <script type="text/javascript"> getBarChartData(5, 10) </script> </div> <div class="model"> <div class="component-card chart-card shop" id="shopDrug-card" style="--color: #07AEA0;"> <div class="title"> <h3 class="title-name">2023年全国药店零售数据</h3> <div class="more"><a target="_blank" rel="nofollow" href="https://vip.pharnexcloud.com/database/ydsale?auto=1&from=menhu">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="chart-content"> <div class="yAxis">药品名称</div> <div class="xAxis">销售额(亿元)</div> <div class="chart" id="shopDrug-chart"></div> </div> <div class="footer-data"> <span>数据来源：<span class="source"></span></span>  </div> </div> </div> <script type="text/javascript"> getBarChartData(6, 10) </script> </div> <div class="images"> <a onclick="advertAddClick(21)" target="_blank" rel="nofollow" href="https://open.bcpmdata.com/" ><img src="https://yaorongyun-public.oss-cn-shanghai.aliyuncs.com/images/ad_images/202504/07/a8d720ce3d309a47ebf7d7091d473cf9.png" alt="摩熵数科开放平台"></a> </div> <div class="model"> <div class="component-card list-card-2" id="annualReport-card" style="--color: #FF5757;"> <div class="title"> <h3 class="title-name">上市企业最新年报</h3> <div class="more"><a href="https://www.pharnexcloud.com/data/qynb">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="swiper"> <ul class="swiper-wrapper list"> </ul> </div> </div> </div> <script> getCardData('annualReport').then(() => { new Swiper("#annualReport-card .swiper", { loop: true, slidesPerView: 5, loopFillGroupWithBlank: true, loopAdditionalSlides: 5, direction: 'vertical', // 设置轮播方向 grabCursor: true, freeMode: false, speed: 3000, autoplay: { delay: 0, disableOnInteraction: false } }) }) </script> </div> <div class="model"> <div class="component-card list-card-2" id="manufacturer-card" style="--color: #07AEA0;"> <div class="title"> <h3 class="title-name">热门药品生产企业</h3> <div class="more"><a href="https://www.pharnexcloud.com/data/scqy">更多<i class="icon iconfont icon-gengduodanjiantou"></i></a></div> </div> <div class="card-content"> <div class="swiper"> <ul class="swiper-wrapper list"> </ul> </div> </div> </div> <script> getCardData('manufacturer').then(() => { new Swiper("#manufacturer-card .swiper", { loop: true, slidesPerView: 5, loopFillGroupWithBlank: true, loopAdditionalSlides: 5, direction: 'vertical', // 设置轮播方向 grabCursor: true, freeMode: false, speed: 3000, autoplay: { delay: 0, disableOnInteraction: false } }) }) </script> </div> </div> </div> </div>   <div id="footer"> <div class="service"> <div class="content"> <div class="content-item icon"> <img src="https://www.pharnexcloud.com/assets/images/common/logo-green5.png" alt="摩熵医药,生物医药全产业链数据服务平台" class="logo"/> </div> <div class="content-item left"> <div class="list"> <div class="title">摩熵数据</div> <div class="list-item"> <a href="https://data.pharnexcloud.com/1/table/44" rel="nofollow" target="_blank">药品研发</a> <a href="https://data.pharnexcloud.com/7/table/153" rel="nofollow" target="_blank">全球上市</a> <a href="https://pharma.bcpmdata.com/?from=menhu" rel="nofollow" target="_blank">药品销售</a> <a href="https://data.pharnexcloud.com/4/table/211" rel="nofollow" target="_blank">市场信息</a> <a href="https://data.pharnexcloud.com/11/table/25" rel="nofollow" target="_blank">一致性评价</a> <a href="https://data.pharnexcloud.com/9/table/207" rel="nofollow" target="_blank">原料药</a> <a href="https://data.pharnexcloud.com/2/table/128" rel="nofollow" target="_blank">生产检验</a> <a href="https://pharma.bcpmdata.com/?from=menhu" rel="nofollow" target="_blank">中药</a> </div> </div> <div class="list"> <div class="title">专题数据库</div> <div class="list-item"> <a href="https://med.bcpmdata.com" rel="nofollow" target="_blank">摩熵医学</a> <a href="https://patent.bcpmdata.com" rel="nofollow" target="_blank">摩熵专利</a> <a href="https://vip.pharnexcloud.com/special/apipharma" rel="nofollow" target="_blank">摩熵原料药</a> <a href="https://invest.bcpmdata.com/home" rel="nofollow" target="_blank">摩熵投融资</a> <a href="https://bio-db.bcpmdata.com" rel="nofollow" target="_blank">摩熵生物</a> <a href="https://vip-mdenter.bcpmdata.com" rel="nofollow" target="_blank">摩熵医械</a> </div> <div class="title">数据服务</div> <div class="list-item"> <a href="https://open.bcpmdata.com" rel="nofollow" target="_blank">数据开放平台</a> </div> </div> <div class="list"> <div class="title">摩熵咨询</div> <div class="list-item"> <a href="https://consult.pharnexcloud.com/service/item" target="_blank">产品立项评估及管线规划</a> <a href="https://consult.pharnexcloud.com/service/survey" target="_blank">产业/行业调研</a> <a href="https://consult.pharnexcloud.com/service/data" target="_blank">数据定制</a> <a href="https://consult.pharnexcloud.com/service/insight" target="_blank">市场洞察</a> </div> <div class="title">医疗数据</div> <div class="list-item"> <a href="https://consult.pharnexcloud.com/medical" target="_blank">真实世界数据</a> </div> </div> <div class="list"> <div class="title">资源中心</div> <div class="list-item"> <a href="https://consult.pharnexcloud.com/live" target="_blank">摩熵说直播</a> <a href="https://consult.pharnexcloud.com/report" target="_blank">报告大厅</a> </div> <div class="title">关于我们</div> <div class="list-item"> <a href="https://www.pharnexcloud.com/about/about" target="_blank">公司介绍</a> <a href="https://www.pharnexcloud.com/about/relate" target="_blank">联系我们</a> <a href="https://www.pharnexcloud.com/join" target="_blank">加入我们</a> <a href="https://www.pharnexcloud.com/about/product" target="_blank">产品与服务</a> <a href="https://www.pharnexcloud.com/about/team" target="_blank">团队介绍</a> </div> </div> </div> <div class="content-item mid"> <div class="list txt"> <img src="https://www.pharnexcloud.com/assets/images/common/foot_img1.png" alt=""> <div> <div class="title">购买咨询</div> <div class="list-item"> <p>18983288589（微信同号）</p> </div> </div> </div> <div class="list txt"> <img src="https://www.pharnexcloud.com/assets/images/common/foot_img2.png" alt=""> <div> <div class="title">商务合作</div> <div class="list-item"> <p>18983288589（微信同号）</p> </div> </div> </div> <div class="list txt"> <img src="https://www.pharnexcloud.com/assets/images/common/foot_img3.png" alt=""> <div> <div class="title">售后服务</div> <div class="list-item"> <p>18908392210（微信同号）</p> </div> </div> </div> <div class="list txt"> <img src="https://www.pharnexcloud.com/assets/images/common/foot_img4.png" alt=""> <div> <div class="title">投诉建议</div> <div class="list-item"> <p>18980413049</p> </div> </div> </div> </div> <div class="content-item right"> <div class="list"> <div class="list-item"> <p> <img src="https://www.pharnexcloud.com/assets/images/common/wxgzh-code.png" alt=""> </p> <div class="title">关注摩熵医药公众号</div> <div class="desc">随时查阅行业资讯</div> </div> </div> <div class="list"> <div class="list-item no_gap"> <p> <img src="https://www.pharnexcloud.com/assets/images/common/weapp-code.png" alt=""> </p> <div class="title">摩熵医药数据小程序</div> <div class="desc">掌上数据查询系统</div> </div> </div> </div> </div> </div> <div class="footer"> <span>《互联网药品信息服务资格证》证书号：（浙）-经营性-2021-0028</span> <a target="_blank" href="https://beian.miit.gov.cn" rel="nofollow"> ICP备案号：蜀ICP备2021004927号-4</a> <a target="_blank" href="http://www.beian.gov.cn/portal/registerSystemInfo?recordcode=33011002015279" rel="nofollow"><img class="icon" src="https://www.pharnexcloud.com/assets/images/common/c5a2d00b7aa8f9245f914a72c046415f.png" alt=""> 浙公网安备33011002015279</a> <span class="item3" style="margin-left: 16px;"></span> <p style="margin-top: 12px;"><img class="icon" src="https://www.pharnexcloud.com/assets/images/common/notice.png" alt=""> 本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息</p> <div class="line"></div> <p class="link"> <span v-if="!links.length">友情链接:</span> <a target="_blank" href="https://www.pharnexcloud.com/" >摩熵医药</a> <a target="_blank" href="https://vip.pharnexcloud.com/" >摩熵医药企业版</a> <a target="_blank" href="https://www.molaid.com/" >摩熵化学MolAid</a> <a target="_blank" href="https://mat.bcpmdata.com/" >晓材Matmole</a> <a target="_blank" href="https://med.bcpmdata.com/" >摩熵医学MedXYZ</a> <a target="_blank" href="http://www.biofeng.com" >载体质粒</a> <a target="_blank" href="https://www.mijian360.com/" >觅健肿瘤互助</a> <a target="_blank" href="https://www.vbdata.cn" >动脉网</a> <a target="_blank" href="https://yao86.com" >药物百科</a> </p> </div> </div>  </div> </div>  <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/zdCascader.js?v=20250403"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/common/footer.js?v=20250403"></script> <script type="text/javascript"> //定义加载区域 // $(document).pjax('a','#pjax-container'); //定义pjax有效时间，超过这个时间会整页刷新 // $.pjax.defaults.timeout = 1200; // if (window.navigator.userAgent.match(/(iPhone|iPod|Android|ios|iPad)/i)) { // setRootFont() // $('.layerMouse').hide() // eruda.init() // } </script>   <script> var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?6f89e9c3aa441e1eea30c4bbfe2b0907"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); </script> <script> // 图表阻止默认的右键菜单 Array.from($('.chart')).forEach(element => { element.addEventListener('contextmenu', function(event) { // 阻止默认的右键菜单 event.preventDefault(); }); }) </script> <script> function fixedClose () { localStorage.setItem('notification', 'close') $('.fixed-img').hide() $('.fixed-img-min').show() } function fixedShow () { localStorage.setItem('notification', 'open') $('.fixed-img-min').hide() $('.fixed-img').css('display', 'flex') } </script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/common/notification.js?v=20250403"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/common/request/news.js?v=20250403"></script> <script type="text/javascript" src="https://www.pharnexcloud.com/assets/js/medical/index.js?v=20250403"></script> </body> </html>

CINXE.COM

摩熵医药(原药融云)-生物医药全产业链数据服务平台 | 摩熵医药生物医药数据库